<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37718435</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1479-5876</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>17</Day></PubDate></JournalIssue><Title>Journal of translational medicine</Title><ISOAbbreviation>J Transl Med</ISOAbbreviation></Journal><ArticleTitle>Epstein-Barr virus-acquired immunodeficiency in myalgic encephalomyelitis-Is it present in long COVID?</ArticleTitle><Pagination><StartPage>633</StartPage><MedlinePgn>633</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">633</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12967-023-04515-7</ELocationID><Abstract><AbstractText>Both myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS) and long COVID (LC) are characterized by similar immunological alterations, persistence of chronic viral infection, autoimmunity, chronic inflammatory state, viral reactivation, hypocortisolism, and microclot formation. They also present with similar symptoms such as asthenia, exercise intolerance, sleep disorders, cognitive dysfunction, and neurological and gastrointestinal complaints. In addition, both pathologies present Epstein-Barr virus (EBV) reactivation, indicating the possibility of this virus being the link between both pathologies. Therefore, we propose that latency and recurrent EBV reactivation could generate an acquired immunodeficiency syndrome in three steps: first, an acquired EBV immunodeficiency develops in individuals with "weak" EBV HLA-II haplotypes, which prevents the control of latency I cells. Second, ectopic lymphoid structures with EBV latency form in different tissues (including the CNS), promoting inflammatory responses and further impairment of cell-mediated immunity. Finally, immune exhaustion occurs due to chronic exposure to viral antigens, with consolidation of the disease. In the case of LC, prior to the first step, there is the possibility of previous SARS-CoV-2 infection in individuals with "weak" HLA-II haplotypes against this virus and/or EBV.</AbstractText><CopyrightInformation>&#xa9; 2023. BioMed Central Ltd., part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ruiz-Pablos</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6605-6611</Identifier><AffiliationInfo><Affiliation>Universidad Complutense de Madrid, Madrid, Spain. manruipa@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paiva</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Clinica Universidad de Navarra, Centro de Investigaci&#xf3;n M&#xe9;dica Aplicada (CIMA), IdiSNA, Instituto de Investigaci&#xf3;n Sanitaria de Navarra, Av. P&#xed;o XII 55, 31008, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zabaleta</LastName><ForeName>Aintzane</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinica Universidad de Navarra, Centro de Investigaci&#xf3;n M&#xe9;dica Aplicada (CIMA), IdiSNA, Instituto de Investigaci&#xf3;n Sanitaria de Navarra, Av. P&#xed;o XII 55, 31008, Pamplona, Spain. azabaletaa@unav.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Transl Med</MedlineTA><NlmUniqueID>101190741</NlmUniqueID><ISSNLinking>1479-5876</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015673" MajorTopicYN="Y">Fatigue Syndrome, Chronic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020031" MajorTopicYN="Y">Epstein-Barr Virus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chronic fatigue syndrome</Keyword><Keyword MajorTopicYN="N">EBV EBNA-1</Keyword><Keyword MajorTopicYN="N">HLA-II alleles</Keyword><Keyword MajorTopicYN="N">Immunodeficiency</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Long COVID syndrome</Keyword><Keyword MajorTopicYN="N">Myalgic encephalomyelitis</Keyword><Keyword MajorTopicYN="N">Post-acute COVID-19 syndrome</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>18</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>17</Day><Hour>23</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37718435</ArticleId><ArticleId IdType="pmc">PMC10506247</ArticleId><ArticleId IdType="doi">10.1186/s12967-023-04515-7</ArticleId><ArticleId IdType="pii">10.1186/s12967-023-04515-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lorusso L, Mikhaylova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G. Immunological aspects of chronic fatigue syndrome. Autoimmun Rev. 2009;8(4):287&#x2013;291. doi: 10.1016/j.autrev.2008.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2008.08.003</ArticleId><ArticleId IdType="pubmed">18801465</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr JR. Epstein&#x2013;Barr virus induced gene-2 upregulation identifies a particular subtype of chronic fatigue syndrome/myalgic encephalomyelitis. Front Pediatr. 2019;7(MAR):59. doi: 10.3389/fped.2019.00059.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2019.00059</ArticleId><ArticleId IdType="pmc">PMC6424879</ArticleId><ArticleId IdType="pubmed">30918887</ArticleId></ArticleIdList></Reference><Reference><Citation>Timbol CR, Baraniuk JN. Chronic fatigue syndrome in the emergency department. Open Access Emerg Med. 2019;11:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6333158</ArticleId><ArticleId IdType="pubmed">30666170</ArticleId></ArticleIdList></Reference><Reference><Citation>Stussman B, Williams A, Snow J, Gavin A, Scott R, Nath A, et al. Characterization of post-exertional malaise in patients with myalgic encephalomyelitis/chronic fatigue syndrome. Front Neurol. 2020;11:1025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7530890</ArticleId><ArticleId IdType="pubmed">33071931</ArticleId></ArticleIdList></Reference><Reference><Citation>Poenaru S, Abdallah SJ, Corrales-Medina V, Cowan J. COVID-19 and post-infectious myalgic encephalomyelitis/chronic fatigue syndrome: a narrative review. Ther Adv Infect Dis. 2021 doi: 10.1177/20499361211009385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20499361211009385</ArticleId><ArticleId IdType="pmc">PMC8060761</ArticleId><ArticleId IdType="pubmed">33959278</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdez AR, Hancock EE, Adebayo S, Kiernicki DJ, Proskauer D, Attewell JR, et al. Estimating prevalence, demographics, and costs of ME/CFS using large scale medical claims data and machine learning. Front Pediatr. 2019;6(JAN):412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6331450</ArticleId><ArticleId IdType="pubmed">30671425</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakken IJ, Tveito K, Gunnes N, Ghaderi S, Stoltenberg C, Trogstad L, et al. Two age peaks in the incidence of chronic fatigue syndrome/myalgic encephalomyelitis: a population-based registry study from Norway 2008&#x2013;2012. BMC Med. 2014;12(1):167. doi: 10.1186/s12916-014-0167-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-014-0167-5</ArticleId><ArticleId IdType="pmc">PMC4189623</ArticleId><ArticleId IdType="pubmed">25274261</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Pablos M, Paiva B, Montero-Mateo R, Garcia N, Zabaleta A. Epstein&#x2013;Barr virus and the origin of myalgic encephalomyelitis or chronic fatigue syndrome. Front Immunol. 2021;12:4637. doi: 10.3389/fimmu.2021.656797.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.656797</ArticleId><ArticleId IdType="pmc">PMC8634673</ArticleId><ArticleId IdType="pubmed">34867935</ArticleId></ArticleIdList></Reference><Reference><Citation>Sairenji T, Yamanishi K, Tachibana Y, Bertoni G, Kurata T. Antibody responses to Epstein&#x2013;Barr virus, human herpesvirus 6 and human herpesvirus 7 in patients with chronic fatigue syndrome. Intervirology. 1995;38(5):269&#x2013;273. doi: 10.1159/000150450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000150450</ArticleId><ArticleId IdType="pubmed">8724857</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariza ME. Myalgic encephalomyelitis/chronic fatigue syndrome: the human herpesviruses are back! Biomolecules. 2021;11(2):1&#x2013;17. doi: 10.3390/biom11020185.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11020185</ArticleId><ArticleId IdType="pmc">PMC7912523</ArticleId><ArticleId IdType="pubmed">33572802</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox BS, Alharshawi K, Mena-Palomo I, Lafuse WP, Ariza ME. EBV/HHV-6A dUTPases contribute to myalgic encephalomyelitis/chronic fatigue syndrome pathophysiology by enhancing TFH cell differentiation and extrafollicular activities. JCI insight. 2022;7(11):e158193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9220958</ArticleId><ArticleId IdType="pubmed">35482424</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, Vernon SD, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006;333(7568):575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1569956</ArticleId><ArticleId IdType="pubmed">16950834</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin P, Williams MV, Klimas NG, Fletcher MA, Barnes Z, Ariza ME. Myalgic encephalomyelitis/chronic fatigue syndrome and gulf war illness patients exhibit increased humoral responses to the herpesviruses-encoded dUTPase: Implications in disease pathophysiology. J Med Virol. 2017;89(9):1636&#x2013;1645. doi: 10.1002/jmv.24810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24810</ArticleId><ArticleId IdType="pmc">PMC5513753</ArticleId><ArticleId IdType="pubmed">28303641</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones JF, Ray CG, Minnich LL, Hicks MJ, Kibler R, Lucas DO. Evidence for active Epstein&#x2013;Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies. Ann Intern Med. 1985;102(1):1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">2578266</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai K, Kawai A. Studies on the relationship between chronic fatigue syndrome and Epstein&#x2013;Barr virus in Japan. Intern Med. 1992;31(3):313&#x2013;318. doi: 10.2169/internalmedicine.31.313.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.31.313</ArticleId><ArticleId IdType="pubmed">1319246</ArticleId></ArticleIdList></Reference><Reference><Citation>Kogelnik AM, Loomis K, Hoegh-Petersen M, Rosso F, Hischier C, Montoya JG. Use of valganciclovir in patients with elevated antibody titers against human herpesvirus-6 (HHV-6) and Epstein&#x2013;Barr virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. J Clin Virol. 2006;37(Suppl 1):S33&#x2013;S38.</Citation><ArticleIdList><ArticleId IdType="pubmed">17276366</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerner AM, Beqaj SH, Deeter RG, Fitzgerald JT. IgM serum antibodies to Epstein&#x2013;Barr virus are uniquely present in a subset of patients with the chronic fatigue syndrome. In Vivo (Brooklyn) 2004;18(2):101&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">15113035</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerner AM, Ariza ME, Williams M, Jason L, Beqaj S, Fitzgerald JT, et al. Antibody to Epstein&#x2013;Barr virus deoxyuridine triphosphate nucleotidohydrolase and deoxyribonucleotide polymerase in a chronic fatigue syndrome subset. PLoS ONE. 2012;7(11):e47891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498272</ArticleId><ArticleId IdType="pubmed">23155374</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchwald D, Cheney PR, Peterson DL, Henry B, Wormsley SB, Geiger A, et al. A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection. Ann Intern Med. 1992;116(2):103&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">1309285</ArticleId></ArticleIdList></Reference><Reference><Citation>Loebel M, Eckey M, Sotzny F, Hahn E, Bauer S, Grabowski P, et al. Serological profiling of the EBV immune response in chronic fatigue syndrome using a peptide microarray. PLoS ONE. 2017;12(6):e0179124. doi: 10.1371/journal.pone.0179124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0179124</ArticleId><ArticleId IdType="pmc">PMC5467847</ArticleId><ArticleId IdType="pubmed">28604802</ArticleId></ArticleIdList></Reference><Reference><Citation>Loebel M, Strohschein K, Giannini C, Koelsch U, Bauer S, Doebis C, et al. Deficient EBV-specific B- and T-cell response in patients with chronic fatigue syndrome. PLoS ONE. 2014;9(1):85387. doi: 10.1371/journal.pone.0085387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0085387</ArticleId><ArticleId IdType="pmc">PMC3893202</ArticleId><ArticleId IdType="pubmed">24454857</ArticleId></ArticleIdList></Reference><Reference><Citation>Manian FA. Simultaneous measurement of antibodies to Epstein&#x2013;Barr virus, human herpesvirus 6, herpes simplex virus types 1 and 2, and 14 enteroviruses in chronic fatigue syndrome: is there evidence of activation of a nonspecific polyclonal immune response? Clin Infect Dis. 1994;19(3):448&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">7811864</ArticleId></ArticleIdList></Reference><Reference><Citation>Shikova E, Reshkova V, Kumanova A, Raleva S, Alexandrova D, Capo N, et al. Cytomegalovirus, Epstein&#x2013;Barr virus, and human herpesvirus-6 infections in patients with myalgic encephalomyelitis/chronic fatigue syndrome. J Med Virol. 2020;92(12):3682&#x2013;3688. doi: 10.1002/jmv.25744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25744</ArticleId><ArticleId IdType="pmc">PMC7687071</ArticleId><ArticleId IdType="pubmed">32129496</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotzny F, Blanco J, Capelli E, Castro-Marrero J, Steiner S, Murovska M, et al. Myalgic encephalomyelitis/chronic fatigue syndrome&#x2014;evidence for an autoimmune disease. Autoimmun Rev. 2018;17(6):601&#x2013;609. doi: 10.1016/j.autrev.2018.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2018.01.009</ArticleId><ArticleId IdType="pubmed">29635081</ArticleId></ArticleIdList></Reference><Reference><Citation>Straus SE, Tosato G, Armstrong G, Lawley T, Preble OT, Henle W, et al. Persisting illness and fatigue in adults with evidence of Epstein&#x2013;Barr virus infection. Ann Intern Med. 1985;102(1):7&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">2578268</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams PhDMV, Cox B, Lafuse PhD WP, Ariza ME. Epstein&#x2013;Barr virus dUTPase induces neuroinflammatory mediators: implications for myalgic encephalomyelitis/chronic fatigue syndrome. Clin Ther. 2019;41(5):848&#x2013;863. doi: 10.1016/j.clinthera.2019.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2019.04.009</ArticleId><ArticleId IdType="pmc">PMC6525645</ArticleId><ArticleId IdType="pubmed">31040055</ArticleId></ArticleIdList></Reference><Reference><Citation>Wray BB, Gaughf C, Chandler FW, Jr, Berry SS, Latham JE, Wood L, et al. Detection of Epstein&#x2013;Barr virus and cytomegalovirus in patients with chronic fatigue. Ann Allergy. 1993;71(3):223&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">8396863</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers BM, Van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. Myalgic encephalomyelitis: international consensus criteria. J Intern Med. 2011;270(4):327&#x2013;338. doi: 10.1111/j.1365-2796.2011.02428.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2011.02428.x</ArticleId><ArticleId IdType="pmc">PMC3427890</ArticleId><ArticleId IdType="pubmed">21777306</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravelsina S, Vilmane A, Svirskis S, Rasa-Dzelzkaleja S, Nora-Krukle Z, Vecvagare K, et al. Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome. Front Immunol. 2022;13:928945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9589447</ArticleId><ArticleId IdType="pubmed">36300129</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasimir F, Toomey D, Liu Z, Kaiping AC, Ariza ME, Prusty BK. Tissue specific signature of HHV-6 infection in ME/CFS. Front Mol Biosci. 2022;9:1044964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9795011</ArticleId><ArticleId IdType="pubmed">36589231</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff AL. Chronic fatigue syndromes: relationship to chronic viral infections. J Virol Methods. 1988;21(1&#x2013;4):3&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">2846619</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner M, Krueger GRF, Ablashi DV, Whitman JE. Chronic fatigue syndrome (CFS): a critical evaluation of testing for active human herpesvirus-6 (HHV-6) infection. J Chronic Fatigue Syndr. 2011;2(4):3&#x2013;16. doi: 10.1300/J092v02n04_02.</Citation><ArticleIdList><ArticleId IdType="doi">10.1300/J092v02n04_02</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes JM, Kell DB, Pretorius E. Cardiovascular and haematological pathology in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a role for viruses. Blood Rev. 2023;60:101075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10027292</ArticleId><ArticleId IdType="pubmed">36963989</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasa S, Nora-Krukle Z, Henning N, Eliassen E, Shikova E, Harrer T, et al. Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) J Transl Med. 2018;16(1):268. doi: 10.1186/s12967-018-1644-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-018-1644-y</ArticleId><ArticleId IdType="pmc">PMC6167797</ArticleId><ArticleId IdType="pubmed">30285773</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes Rivera M, Mastronardi C, Silva-Aldana C, Arcos-Burgos M, Lidbury B. Myalgic encephalomyelitis/chronic fatigue syndrome: a comprehensive review. Diagnostics. 2019;9(3):91. doi: 10.3390/diagnostics9030091.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics9030091</ArticleId><ArticleId IdType="pmc">PMC6787585</ArticleId><ArticleId IdType="pubmed">31394725</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Harding S, Sorenson M, Jason LA, Maher K, Fletcher MA. Evidence for T-helper 2 shift and association with illness parameters in chronic fatigue syndrome (CFS) Bull IACFS ME. 2008;16(3):19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3018761</ArticleId><ArticleId IdType="pubmed">21234277</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Yang Y, Wang D, Li C, Qu Y, Guo J, et al. The clinical value of cytokines in chronic fatigue syndrome. J Transl Med. 2019;17(1):213. doi: 10.1186/s12967-019-1948-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-019-1948-6</ArticleId><ArticleId IdType="pmc">PMC6599310</ArticleId><ArticleId IdType="pubmed">31253154</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong N, Nguyen T, Brenu EW, Broadley S, Staines D, Marshall-Gradisnik S, et al. A comparison of cytokine profiles of chronic fatigue syndrome/myalgic encephalomyelitis and multiple sclerosis patients. Int J Clin Med. 2015;6(10):769&#x2013;783.</Citation></Reference><Reference><Citation>Nakatomi Y, Mizuno K, Ishii A, Wada Y, Tanaka M, Tazawa S, et al. Neuroinflammation in patients with chronic fatigue syndrome/myalgic encephalomyelitis: an 11C-(R)-PK11195 PET study. J Nucl Med. 2014;55(6):945&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pubmed">24665088</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenu EW, van Driel ML, Staines DR, Ashton KJ, Hardcastle SL, Keane J, et al. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med. 2012;10(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3464733</ArticleId><ArticleId IdType="pubmed">22571715</ArticleId></ArticleIdList></Reference><Reference><Citation>Broderick G, Fuite J, Kreitz A, Vernon SD, Klimas N, Fletcher MA. A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav Immun. 2010;24(7):1209. doi: 10.1016/j.bbi.2010.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2010.04.012</ArticleId><ArticleId IdType="pmc">PMC2939140</ArticleId><ArticleId IdType="pubmed">20447453</ArticleId></ArticleIdList></Reference><Reference><Citation>Giloteaux L, O&#x2019;Neal A, Castro-Marrero J, Levine SM, Hanson MR. Cytokine profiling of extracellular vesicles isolated from plasma in myalgic encephalomyelitis/chronic fatigue syndrome: a pilot study. J Transl Med. 2020;18(1):1&#x2013;17. doi: 10.1186/s12967-020-02560-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02560-0</ArticleId><ArticleId IdType="pmc">PMC7552484</ArticleId><ArticleId IdType="pubmed">33046133</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff AL. Inflammation correlates with symptoms in chronic fatigue syndrome. Proc Natl Acad Sci USA. 2017;114(34):8914&#x2013;8916. doi: 10.1073/pnas.1712475114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1712475114</ArticleId><ArticleId IdType="pmc">PMC5576849</ArticleId><ArticleId IdType="pubmed">28811366</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandarano AH, Maya J, Giloteaux L, Peterson DL, Maynard M, Gottschalk CG, et al. Myalgic encephalomyelitis/chronic fatigue syndrome patients exhibit altered T cell metabolism and cytokine associations. J Clin Invest. 2020;130(3):1491&#x2013;1505. doi: 10.1172/JCI132185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI132185</ArticleId><ArticleId IdType="pmc">PMC7269566</ArticleId><ArticleId IdType="pubmed">31830003</ArticleId></ArticleIdList></Reference><Reference><Citation>Patarca R. Cytokines and chronic fatigue syndrome. Ann N Y Acad Sci. 2001;933:185&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">12000020</ArticleId></ArticleIdList></Reference><Reference><Citation>Skowera A, Cleare A, Blair D, Bevis L, Wessely SC, Peakman M. High levels of type 2 cytokine-producing cells in chronic fatigue syndrome. Clin Exp Immunol. 2004;135(2):294&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1808936</ArticleId><ArticleId IdType="pubmed">14738459</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Harding S, Sorenson M, Jason L, Maher K, Fletcher M, Reynolds N, et al. The associations between basal salivary cortisol and illness symptomatology in chronic fatigue syndrome. J Appl Biobehav Res. 2008;13(3):157&#x2013;180. doi: 10.1111/j.1751-9861.2008.00033.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1751-9861.2008.00033.x</ArticleId><ArticleId IdType="pmc">PMC2730359</ArticleId><ArticleId IdType="pubmed">19701493</ArticleId></ArticleIdList></Reference><Reference><Citation>Nijhof SL, Rutten JMTM, Uiterwaal CSPM, Bleijenberg G, Kimpen JLL, van de Putte EM. The role of hypocortisolism in chronic fatigue syndrome. Psychoneuroendocrinology. 2014;42:199&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">24636516</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell DJH, Liossi C, Moss-Morris R, Schlotz W. Unstimulated cortisol secretory activity in everyday life and its relationship with fatigue and chronic fatigue syndrome: a systematic review and subset meta-analysis. Psychoneuroendocrinology. 2013;38(11):2405&#x2013;2422.</Citation><ArticleIdList><ArticleId IdType="pubmed">23916911</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts ADL, Wessely S, Chalder T, Papadopoulos A, Cleare AJ. Salivary cortisol response to awakening in chronic fatigue syndrome. Br J Psychiatry. 2004;184(FEB):136&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">14754825</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts ADL, Charler ML, Papadopoulos A, Wessely S, Chalder T, Cleare AJ. Does hypocortisolism predict a poor response to cognitive behavioural therapy in chronic fatigue syndrome? Psychol Med. 2010;40(3):515&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">19607750</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomas C, Newton J, Watson S. A review of hypothalamic&#x2013;pituitary&#x2013;adrenal axis function in chronic fatigue syndrome. ISRN Neurosci. 2013;2013:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4045534</ArticleId><ArticleId IdType="pubmed">24959566</ArticleId></ArticleIdList></Reference><Reference><Citation>Tak LM, Cleare AJ, Ormel J, Manoharan A, Kok IC, Wessely S, et al. Meta-analysis and meta-regression of hypothalamic&#x2013;pituitary&#x2013;adrenal axis activity in functional somatic disorders. Biol Psychol. 2011;87(2):183&#x2013;194. doi: 10.1016/j.biopsycho.2011.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsycho.2011.02.002</ArticleId><ArticleId IdType="pubmed">21315796</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G, Anderson G, Maes M. Hypothalamic&#x2013;pituitary&#x2013;adrenal hypofunction in myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) as a consequence of activated immune-inflammatory and oxidative and nitrosative pathways. Mol Neurobiol. 2017;54(9):6806&#x2013;6819. doi: 10.1007/s12035-016-0170-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0170-2</ArticleId><ArticleId IdType="pubmed">27766535</ArticleId></ArticleIdList></Reference><Reference><Citation>Gur A, Cevik R, Nas K, Colpan L, Sarac S. Cortisol and hypothalamic&#x2013;pituitary&#x2013;gonadal axis hormones in follicular-phase women with fibromyalgia and chronic fatigue syndrome and effect of depressive symptoms on these hormones. Arthritis Res Ther. 2004;6(3):R232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC416440</ArticleId><ArticleId IdType="pubmed">15142269</ArticleId></ArticleIdList></Reference><Reference><Citation>Jason L, Sorenson M, Sebally K, Alkazemi D, Lerch A, Porter N, et al. Increased HDAC in association with decreased plasma cortisol in older adults with chronic fatigue syndrome. Brain Behav Immun. 2011;25(8):1544&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">21549189</ArticleId></ArticleIdList></Reference><Reference><Citation>Jerjes WK, Cleare AJ, Wessely S, Wood PJ, Taylor NF. Diurnal patterns of salivary cortisol and cortisone output in chronic fatigue syndrome. J Affect Disord. 2005;87(2&#x2013;3):299&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">15922454</ArticleId></ArticleIdList></Reference><Reference><Citation>Maloney EM, Boneva RS, Lin JMS, Reeves WC. Chronic fatigue syndrome is associated with metabolic syndrome: results from a case&#x2013;control study in Georgia. Metabolism. 2010;59(9):1351&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">20102774</ArticleId></ArticleIdList></Reference><Reference><Citation>Nater UM, Youngblood LS, Jones JF, Unger ER, Miller AH, Reeves WC, et al. Alterations in diurnal salivary cortisol rhythm in a population-based sample of cases with chronic fatigue syndrome. Psychosom Med. 2008;70(3):298&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">18378875</ArticleId></ArticleIdList></Reference><Reference><Citation>Nater UM, Maloney E, Boneva RS, Gurbaxani BM, Lin JM, Jones JF, et al. Attenuated morning salivary cortisol concentrations in a population-based study of persons with chronic fatigue syndrome and well controls. J Clin Endocrinol Metab. 2008;93(3):703&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">18160468</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinov K, Von Mikecz A, Buchwald D, Jones J, Gerace L, Tan EM. Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome. J Clin Invest. 1996;98(8):1888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC507629</ArticleId><ArticleId IdType="pubmed">8878441</ArticleId></ArticleIdList></Reference><Reference><Citation>Loebel M, Grabowski P, Heidecke H, Bauer S, Hanitsch LG, Wittke K, et al. Antibodies to &#x3b2; adrenergic and muscarinic cholinergic receptors in patients with chronic fatigue syndrome. Brain Behav Immun. 2016;52:32&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">26399744</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M, Mihaylova I, Leunis JC. Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neopitopes formed by oxidative or nitrosative damage to lipids and proteins. Neuro Endocrinol Lett. 2006;27(5):615&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pubmed">17159817</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M, Mihaylova I, Kubera M, Leunis JC, Twisk FNM, Geffard M. IgM-mediated autoimmune responses directed against anchorage epitopes are greater in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) than in major depression. Metab Brain Dis. 2012;27(4):415&#x2013;423. doi: 10.1007/s11011-012-9316-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-012-9316-8</ArticleId><ArticleId IdType="pubmed">22614823</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G, Berk M, Galecki P, Maes M. The emerging role of autoimmunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/cfs) Mol Neurobiol. 2014;49(2):741&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">24068616</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishikai M, Tomomatsu S, Hankins RW, Takagi S, Miyachi K, Kosaka S, et al. Autoantibodies to a 68/48 kDa protein in chronic fatigue syndrome and primary fibromyalgia: a possible marker for hypersomnia and cognitive disorders. Rheumatology. 2001;40(7):806&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">11477286</ArticleId></ArticleIdList></Reference><Reference><Citation>Op De Be&#xe9;ck K, Vermeersch P, Verschueren P, Westhovens R, Mari&#xeb;n G, Blockmans D, et al. Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis. Autoimmun Rev. 2012;12(2):137&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">22387973</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoenfeld Y, Ryabkova VA, Scheibenbogen C, Brinth L, Martinez-Lavin M, Ikeda S, et al. Complex syndromes of chronic pain, fatigue and cognitive impairment linked to autoimmune dysautonomia and small fiber neuropathy. Clin Immunol. 2020;214:108384.</Citation><ArticleIdList><ArticleId IdType="pubmed">32171889</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka S, Kuratsune H, Hidaka Y, Hakariya Y, Tatsumi KI, Takano T, et al. Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome. Int J Mol Med. 2003;12(2):225&#x2013;230. doi: 10.3892/ijmm.12.2.225/abstract.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.12.2.225/abstract</ArticleId><ArticleId IdType="pubmed">12851722</ArticleId></ArticleIdList></Reference><Reference><Citation>Underhill RA. Myalgic encephalomyelitis, chronic fatigue syndrome: an infectious disease. Med Hypotheses. 2015;85(6):765&#x2013;773. doi: 10.1016/j.mehy.2015.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2015.10.011</ArticleId><ArticleId IdType="pubmed">26604026</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Mikecz A, Konstantinov K, Buchwald DS, Gerace L, Tan EM. High frequency of autoantibodies to insoluble cellular antigens in patients with chronic fatigue syndrome. Arthritis Rheum. 1997;40(2):295&#x2013;305. doi: 10.1002/art.1780400215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400215</ArticleId><ArticleId IdType="pubmed">9041942</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto S, Ouchi Y, Nakatsuka D, Tahara T, Mizuno K, Tajima S, et al. Reduction of [11C](+)3-MPB binding in brain of chronic fatigue syndrome with serum autoantibody against muscarinic cholinergic receptor. PLoS ONE. 2012;7(12):e51515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3519853</ArticleId><ArticleId IdType="pubmed">23240035</ArticleId></ArticleIdList></Reference><Reference><Citation>Danilenko OV, Gavrilova NY, Churilov LP. Chronic fatigue exhibits heterogeneous autoimmunity characteristics which reflect etiology. Pathophysiology. 2022;29(2):187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9231045</ArticleId><ArticleId IdType="pubmed">35736644</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg J, Gottfries C-G, Elfaitouri A, Rizwan M, Ros&#xe9;n A. Infection elicited autoimmunity and myalgic encephalomyelitis/chronic fatigue syndrome: an explanatory model. Front Immunol. 2018;9(FEB):15. doi: 10.3389/fimmu.2018.00229.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00229</ArticleId><ArticleId IdType="pmc">PMC5818468</ArticleId><ArticleId IdType="pubmed">29497420</ArticleId></ArticleIdList></Reference><Reference><Citation>Hokama Y, Campora CE, Hara C, Kuribayashi T, Le Huynh D, Yabusaki K. Anticardiolipin antibodies in the sera of patients with diagnosed chronic fatigue syndrome. J Clin Lab Anal. 2009;23(4):210&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6649060</ArticleId><ArticleId IdType="pubmed">19623655</ArticleId></ArticleIdList></Reference><Reference><Citation>Hokama Y, Empey-Campora C, Hara C, Higa N, Siu N, Lau R, et al. Acute phase phospholipids related to the cardiolipin of mitochondria in the sera of patients with chronic fatigue syndrome (CFS), chronic Ciguatera fish poisoning (CCFP), and other diseases attributed to chemicals, Gulf War, and marine toxins. J Clin Lab Anal. 2008;22(2):99&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6649096</ArticleId><ArticleId IdType="pubmed">18348309</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R, Berg PA. High incidence of antibodies to 5-hydroxytryptamine, gangliosides and phospholipids in patients with chronic fatigue and fibromyalgia syndrome and their relatives: evidence for a clinical entity of both disorders. Eur J Med Res. 1995;1(1):21&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">9392689</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes JM, Kruger A, Proal A, Kell DB, Pretorius E. The occurrence of hyperactivated platelets and fibrinaloid microclots in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Pharmaceuticals. 2022;15(8):931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9413879</ArticleId><ArticleId IdType="pubmed">36015078</ArticleId></ArticleIdList></Reference><Reference><Citation>Nacul L, O&#x2019;Boyle S, Palla L, Nacul FE, Mudie K, Kingdon CC, et al. How myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) progresses: the natural history of ME/CFS. Front Neurol. 2020;11:826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7431524</ArticleId><ArticleId IdType="pubmed">32849252</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Casals M, Brito-Zer&#xf3;n P, Mariette X. Systemic and organ-specific immune-related manifestations of COVID-19. Nat Rev Rheumatol. 2021;17(6):315&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8072739</ArticleId><ArticleId IdType="pubmed">33903743</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang JJ, Dong X, Liu GH, Gao YD. Risk and protective factors for COVID-19 morbidity, severity, and mortality. Clin Rev Allergy Immunol. 2022;1:1&#x2013;18. doi: 10.1007/s12016-022-08921-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-022-08921-5</ArticleId><ArticleId IdType="pmc">PMC8767775</ArticleId><ArticleId IdType="pubmed">35044620</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng N, Zhao YM, Yan W, Li C, Lu QD, Liu L, et al. A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: call for research priority and action. Mol Psychiatry. 2023;28(1):423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9168643</ArticleId><ArticleId IdType="pubmed">35668159</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Shi L, Jiang Z, Zeng N, Mei H, Lu Y, et al. The phenotype and prediction of long-term physical, mental and cognitive COVID-19 sequelae 20 months after recovery, a community-based cohort study in China. Mol Psychiatry. 2023;28(4):1793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9869317</ArticleId><ArticleId IdType="pubmed">36690792</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6(9):e005427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11(1):1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS, et al. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021;114(9):428&#x2013;442. doi: 10.1177/01410768211032850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/01410768211032850</ArticleId><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4(10):e2128568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Robineau O, Wiernik E, Lemogne C, de Lamballerie X, Ninove L, Blanch&#xe9; H, et al. Persistent symptoms after the first wave of COVID-19 in relation to SARS-CoV-2 serology and experience of acute symptoms: a nested survey in a population-based cohort. Lancet Reg Health Eur. 2022;17:100363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005155</ArticleId><ArticleId IdType="pubmed">35434687</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28(8):1706&#x2013;1714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath A. Long-haul COVID. Neurology. 2020;95(13):559&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pubmed">32788251</ArticleId></ArticleIdList></Reference><Reference><Citation>Aucott JN, Rebman AW. Long-haul COVID: heed the lessons from other infection-triggered illnesses. Lancet. 2021;397(10278):967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7952095</ArticleId><ArticleId IdType="pubmed">33684352</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg P, Arora U, Kumar A, Wig N. The, &#x201c;post-COVID&#x201d; syndrome: how deep is the damage? J Med Virol. 2021;93(2):673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7461449</ArticleId><ArticleId IdType="pubmed">32852801</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker AM, Brigham E, Connolly B, McPeake J, Agranovich AV, Kenes MT, et al. Addressing the post-acute sequelae of SARS-CoV-2 infection: a multidisciplinary model of care. Lancet Respir Med. 2021;9(11):1328&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8525917</ArticleId><ArticleId IdType="pubmed">34678213</ArticleId></ArticleIdList></Reference><Reference><Citation>Cau R, Faa G, Nardi V, Balestrieri A, Puig J, Suri JS, et al. Long-COVID diagnosis: from diagnostic to advanced AI-driven models. Eur J Radiol. 2022;148:110164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8791239</ArticleId><ArticleId IdType="pubmed">35114535</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Toro A, Bozzani A, Tavazzi G, Urtis M, Giuliani L, Pizzoccheri R, et al. Long COVID: long-term effects? Eur Heart J Suppl. 2021;23(Suppl E):E1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8503490</ArticleId><ArticleId IdType="pubmed">34650349</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A, Koch R, Jukic A, Pfister A, Meyer M, R&#xf6;ssler A, et al. Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology. 2022;163(2):495&#x2013;506.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejerina F, Catalan P, Rodriguez-Grande C, Adan J, Rodriguez-Gonzalez C, Mu&#xf1;oz P, et al. Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19. BMC Infect Dis. 2022;22(1):1&#x2013;8. doi: 10.1186/s12879-022-07153-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07153-4</ArticleId><ArticleId IdType="pmc">PMC8892394</ArticleId><ArticleId IdType="pubmed">35240997</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs JJL. Persistent SARS-2 infections contribute to long COVID-19. Med Hypotheses. 2021;149:110538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7884250</ArticleId><ArticleId IdType="pubmed">33621843</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, et al. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis. 2023;76(3):e487&#x2013;e490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung CCL, Goh D, Lim X, Tien TZ, Lim JCT, Lee JN, et al. Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. Gut. 2022;71(1):226&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">34083386</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A, Zlitni S, Brooks EF, Vance SE, Dahlen A, Hedlin H, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med. 2022;3(6):371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612(7941):758&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T, Liu Q, Zhang F, Lui GCY, Tso EYK, Yeoh YK, et al. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. Gut. 2021;70(2):276&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7385744</ArticleId><ArticleId IdType="pubmed">32690600</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeble J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study. Clin Infect Dis. 2022;74(7):1191&#x2013;1198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur JM, Forrest JC, Boehme KW, Kennedy JL, Owens S, Herzog C, et al. Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS ONE. 2021;16(9):e0257016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8415618</ArticleId><ArticleId IdType="pubmed">34478478</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, F&#xfc;rst J, Schulze-Rothe S, Wallukat A, et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent long-COVID-19 symptoms. J Transl Autoimmun. 2021;4:100100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortona E, Buonsenso D, Carfi A, Malorni W. Long COVID: an estrogen-associated autoimmune disease? Cell Death Discov. 2021;7(1):1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8042352</ArticleId><ArticleId IdType="pubmed">33850105</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Ampudia Y, Monsalve DM, Rojas M, Rodriguez Y, Zapata E, Ramirez-Santana C, et al. Persistent autoimmune activation and proinflammatory state in post-coronavirus disease 2019 syndrome. J Infect Dis. 2022;225(12):2155&#x2013;2162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903340</ArticleId><ArticleId IdType="pubmed">35079804</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021;20(4):102792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7892316</ArticleId><ArticleId IdType="pubmed">33610751</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#x2019;Huillier AG, Pagano S, Baggio S, Meyer B, Andrey DO, Nehme M, et al. Autoantibodies against apolipoprotein A-1 after COVID-19 predict symptoms persistence. Eur J Clin Invest. 2022;52(10):e13818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9348059</ArticleId><ArticleId IdType="pubmed">35598178</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisareva E, Badiou S, Mihalovi&#x10d;ov&#xe1; L, Mirandola A, Pastor B, Kudriavtsev A, et al. Persistence of neutrophil extracellular traps and anticardiolipin auto-antibodies in post-acute phase COVID-19 patients. J Med Virol. 2023;95(1):e28209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9874393</ArticleId><ArticleId IdType="pubmed">36226380</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotzny F, Filgueiras IS, Kedor C, Freitag H, Wittke K, Bauer S, et al. Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in post COVID syndrome correlate with symptom severity. Front Immunol. 2022;13:5182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552223</ArticleId><ArticleId IdType="pubmed">36238301</ArticleId></ArticleIdList></Reference><Reference><Citation>Szewczykowski C, Mardin C, Lucio M, Wallukat G, Hoffmanns J, Schr&#xf6;der T, et al. Long COVID: association of functional autoantibodies against G-protein-coupled receptors with an impaired retinal microcirculation. Int J Mol Sci. 2022;23(13):7209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9266742</ArticleId><ArticleId IdType="pubmed">35806214</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595(7866):283&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23(2):210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf; C, Willscher E, Paschold L, Gottschick C, Klee B, Henkes SS, et al. The IL-1&#x3b2;, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med. 2022;3(6):100663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuwa HA, Shaw TN, Knight SB, Wemyss K, McClure FA, Pearmain L, et al. Alterations in T and B cell function persist in convalescent COVID-19 patients. Med. 2021;2(6):720&#x2013;735.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8011689</ArticleId><ArticleId IdType="pubmed">33821250</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Casta&#xf1;eda A, Lu P, Geraghty AC, Song E, Lee M-H, Wood J, et al. Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain. bioRxiv. 2022 doi: 10.1101/2022.01.07.475453v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.07.475453v1</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellan M, Apostolo D, Alb&#xe8; A, Crevola M, Errica N, Ratano G, et al. Determinants of long COVID among adults hospitalized for SARS-CoV-2 infection: a prospective cohort study. Front Immunol. 2022;13:1038227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9807078</ArticleId><ArticleId IdType="pubmed">36601115</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Casta&#xf1;eda A, Lu P, Geraghty AC, Song E, Lee MH, Wood J, et al. Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell. 2022;185(14):2452&#x2013;2468.e16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9189143</ArticleId><ArticleId IdType="pubmed">35768006</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal&#xe1;n M, Vig&#xf3;n L, Fuertes D, Murciano-Ant&#xf3;n MA, Casado-Fern&#xe1;ndez G, Dom&#xed;nguez-Mateos S, et al. Persistent overactive cytotoxic immune response in a spanish cohort of individuals with long-COVID: identification of diagnostic biomarkers. Front Immunol. 2022;13:848886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8990790</ArticleId><ArticleId IdType="pubmed">35401523</ArticleId></ArticleIdList></Reference><Reference><Citation>Low RN, Low RJ, Akrami A. A review of cytokine-based pathophysiology of Long COVID symptoms. Front Med. 2023;10:1011936. doi: 10.3389/fmed.2023.1011936/full.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1011936/full</ArticleId><ArticleId IdType="pmc">PMC10103649</ArticleId><ArticleId IdType="pubmed">37064029</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BK, Guevara-Coto J, Yogendra R, Francisco E, Long E, Pise A, et al. Immune-based prediction of COVID-19 severity and chronicity decoded using machine learning. bioRxiv. 2020 doi: 10.1101/2020.12.16.423122v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.16.423122v1</ArticleId><ArticleId IdType="pmc">PMC8273732</ArticleId><ArticleId IdType="pubmed">34262570</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruenjaiman V, Sodsai P, Kueanjinda P, Bunrasmee W, Klinchanhom S, Reantragoon R, et al. Impact of SARS-CoV-2 infection on the profiles and responses of innate immune cells after recovery. J Microbiol Immunol Infect. 2022;55(6 Pt 1):993&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9519362</ArticleId><ArticleId IdType="pubmed">36220753</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan FJ, Hope CM, Masavuli MG, Lynn MA, Mekonnen ZA, Yeow AEL, et al. Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Med. 2022;20(1):1&#x2013;23. doi: 10.1186/s12916-021-02228-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02228-6</ArticleId><ArticleId IdType="pmc">PMC8758383</ArticleId><ArticleId IdType="pubmed">35027067</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, Wood J, Jaycox J, Lu P, Dhodapkar RM, Gehlhausen JR, et al. Distinguishing features of long COVID identified through immune profiling. medRxiv. 2022 doi: 10.1101/2022.08.09.22278592v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.09.22278592v1</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein&#x2013;Barr virus reactivation. Pathogens. 2021;10(6):763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonnet A, Engelmann I, Moreau AS, Garcia B, Six S, El Kalioubie A, et al. High incidence of Epstein&#x2013;Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19. Infect Dis now. 2021;51(3):296&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816954</ArticleId><ArticleId IdType="pubmed">33495765</ArticleId></ArticleIdList></Reference><Reference><Citation>Khani E, Entezari-Maleki T. Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists. Mol Psychiatry. 2022;27(9):3562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8985056</ArticleId><ArticleId IdType="pubmed">35388182</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K. Detrimental effects of COVID-19 in the brain and therapeutic options for long COVID: the role of Epstein&#x2013;Barr virus and the gut&#x2013;brain axis. Mol Psychiatry. 2023;2023:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11041741</ArticleId><ArticleId IdType="pubmed">37402856</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881&#x2013;895.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolou E, Rizwan M, Moustardas P, Sj&#xf6;gren P, Bertilson BC, Brag&#xe9;e B, et al. Saliva antibody-fingerprint of reactivated latent viruses after mild/asymptomatic COVID-19 is unique in patients with myalgic-encephalomyelitis/chronic fatigue syndrome. Front Immunol. 2022;13:6407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9630598</ArticleId><ArticleId IdType="pubmed">36341457</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B, Tancredi C, Song Y, Mogus AT, Huang MLW, Zhu H, et al. Epstein&#x2013;Barr virus and human herpesvirus-6 reactivation in acute COVID-19 patients. Viruses. 2022;14(9):1872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9504756</ArticleId><ArticleId IdType="pubmed">36146679</ArticleId></ArticleIdList></Reference><Reference><Citation>Carneiro VC, Alves-Leon SV, Sarmento DJ, Coelho WL, Moreira OD, Salvio AL, et al. Herpesvirus and neurological manifestations in patients with severe coronavirus disease. Virol J. 2022;19(1):1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9174631</ArticleId><ArticleId IdType="pubmed">35676707</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. Trends Immunol. 2022;43(4):268&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8901423</ArticleId><ArticleId IdType="pubmed">35272932</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deveau TM, Munter SE, Ryder D, Buck A, Beck-Engeser G, et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest. 2023 doi: 10.1172/JCI163669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI163669</ArticleId><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;12:1494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafiee A, Teymouri Athar MM, Amini MJ, Hajishah H, Siahvoshi S, Jalali M, et al. Reactivation of herpesviruses during COVID-19: a systematic review and meta-analysis. Rev Med Virol. 2023;33(3):e2437.</Citation><ArticleIdList><ArticleId IdType="pubmed">36880642</ArticleId></ArticleIdList></Reference><Reference><Citation>Salzano C, Saracino G, Cardillo G. Possible adrenal involvement in long COVID syndrome. Medicina. 2021;57(10):1087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8537520</ArticleId><ArticleId IdType="pubmed">34684123</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunada N, Honda H, Nakano Y, Yamamoto K, Tokumasu K, Sakurada Y, et al. Hormonal trends in patients suffering from long COVID symptoms. Endocr J. 2022;69(10):1173&#x2013;1181.</Citation><ArticleIdList><ArticleId IdType="pubmed">35491089</ArticleId></ArticleIdList></Reference><Reference><Citation>Yavropoulou MP, Tsokos GC, Chrousos GP, Sfikakis PP. Protracted stress-induced hypocortisolemia may account for the clinical and immune manifestations of long COVID. Clin Immunol. 2022;245:109133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9519365</ArticleId><ArticleId IdType="pubmed">36182048</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobbelaar LM, Venter C, Vlok M, Ngoepe M, Laubscher GJ, Lourens PJ, et al. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19. Biosci Rep. 2021;41(8):20210611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8380922</ArticleId><ArticleId IdType="pubmed">34328172</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D, Di Giuda D, Sigfrid L, Pizzuto DA, Di Sante G, De Rose C, et al. Evidence of lung perfusion defects and ongoing inflammation in an adolescent with post-acute sequelae of SARS-CoV-2 infection. Lancet Child Adolesc Heal. 2021;5(9):677&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8324416</ArticleId><ArticleId IdType="pubmed">34339624</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Vlok M, Venter C, Bezuidenhout JA, Laubscher GJ, Steenkamp J, et al. Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20(1):1&#x2013;18. doi: 10.1186/s12933-021-01359-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01359-7</ArticleId><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell DB, Laubscher GJ, Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochem J. 2022;479(4):537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8883497</ArticleId><ArticleId IdType="pubmed">35195253</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobbelaar LM, Kruger A, Venter C, Burger EM, Laubscher GJ, Maponga TG, et al. Relative hypercoagulopathy of the SARS-CoV-2 beta and delta variants when compared to the less severe omicron variants is related to TEG parameters, the extent of fibrin amyloid microclots, and the severity of clinical illness. Semin Thromb Hemost. 2022;48(7):858&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">36174604</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger A, Vlok M, Turner S, Venter C, Laubscher GJ, Kell DB, et al. Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovasc Diabetol. 2022;21(1):1&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9491257</ArticleId><ArticleId IdType="pubmed">36131342</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrow AK, Malone LA, Kokorelis C, Petracek LS, Eastin EF, Lobner KL, et al. Long-term COVID 19 sequelae in adolescents: the overlap with orthostatic intolerance and ME/CFS. Curr Pediatr Rep. 2022;10(2):31&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8906524</ArticleId><ArticleId IdType="pubmed">35287333</ArticleId></ArticleIdList></Reference><Reference><Citation>Salari N, Khodayari Y, Hosseinian-Far A, Zarei H, Rasoulpoor S, Akbari H, et al. Global prevalence of chronic fatigue syndrome among long COVID-19 patients: a systematic review and meta-analysis. Biopsychosoc Med. 2022;16(1):21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9589726</ArticleId><ArticleId IdType="pubmed">36274177</ArticleId></ArticleIdList></Reference><Reference><Citation>Tate W, Walker M, Sweetman E, Helliwell A, Peppercorn K, Edgar C, et al. Molecular mechanisms of neuroinflammation in ME/CFS and long COVID to sustain disease and promote relapses. Front Neurol. 2022;13:877772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9174654</ArticleId><ArticleId IdType="pubmed">35693009</ArticleId></ArticleIdList></Reference><Reference><Citation>Vernon SD, Hartle M, Sullivan K, Bell J, Abbaszadeh S, Unutmaz D, et al. Post-exertional malaise among people with long COVID compared to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Work. 2023;74(4):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">36911963</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman KJ, Murovska M, Pheby DFH, Zalewski P. Our evolving understanding of ME/CFS. Medicina. 2021;57(3):1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7996879</ArticleId><ArticleId IdType="pubmed">33652622</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff AL, Bateman L. Will COVID-19 lead to myalgic encephalomyelitis/chronic fatigue syndrome? Front Med. 2020;7:606824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7848220</ArticleId><ArticleId IdType="pubmed">33537329</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong TL, Weitzer DJ. Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)&#x2014;a systemic review and comparison of clinical presentation and symptomatology. Medicina. 2021;57(5):418. doi: 10.3390/medicina57050418.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57050418</ArticleId><ArticleId IdType="pmc">PMC8145228</ArticleId><ArticleId IdType="pubmed">33925784</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla H, Quach TC, Tiwari A, Bonilla AE, Miglis M, Yang PC, et al. Myalgic encephalomyelitis/chronic fatigue syndrome is common in post-acute sequelae of SARS-CoV-2 infection (PASC): results from a post-COVID-19 multidisciplinary clinic. Front Neurol. 2023;14:1090747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9998690</ArticleId><ArticleId IdType="pubmed">36908615</ArticleId></ArticleIdList></Reference><Reference><Citation>Jason LA, Dorri JA. ME/CFS and post-exertional malaise among patients with long COVID. Neurol Int. 2023;15(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9844405</ArticleId><ArticleId IdType="pubmed">36648965</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff AL, Lipkin WI. ME/CFS and long COVID share similar symptoms and biological abnormalities: road map to the literature. Front Med. 2023;10:1187163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10278546</ArticleId><ArticleId IdType="pubmed">37342500</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojdani A, Vojdani E, Saidara E, Maes M. Persistent SARS-CoV-2 infection, EBV, HHV-6 and other factors may contribute to inflammation and autoimmunity in long COVID. Viruses. 2023;15(2):400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9967513</ArticleId><ArticleId IdType="pubmed">36851614</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottschalk CG, Peterson D, Armstrong J, Knox K, Roy A. Potential molecular mechanisms of chronic fatigue in long haul COVID and other viral diseases. Infect Agents Cancer. 2023;18(1):1&#x2013;16. doi: 10.1186/s13027-023-00485-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13027-023-00485-z</ArticleId><ArticleId IdType="pmc">PMC9902840</ArticleId><ArticleId IdType="pubmed">36750846</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunn AVW, Guy GW, Botchway SW, Bell JD. SARS-CoV-2 and EBV; the cost of a second mitochondrial &#x201c;whammy&#x201d;? Immun Ageing. 2021;18(1):1&#x2013;4. doi: 10.1186/s12979-021-00252-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-021-00252-x</ArticleId><ArticleId IdType="pmc">PMC8556816</ArticleId><ArticleId IdType="pubmed">34717676</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois RE, Seeley JK, Brus I, Sakamoto K, Ballow M, Harada S, et al. Chronic mononucleosis syndrome. South Med J. 1984;77(11):1376&#x2013;1382. doi: 10.1097/00007611-198411000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00007611-198411000-00007</ArticleId><ArticleId IdType="pubmed">6093268</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson SK, Daly JS, Thorne GM, McIntosh K. Chronic parvovirus B19 infection resulting in chronic fatigue syndrome: case history and review. Clin Infect Dis. 1997;24(6):1048&#x2013;1051. doi: 10.1086/513627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/513627</ArticleId><ArticleId IdType="pubmed">9195056</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega-Hernandez O-D, Shoenfeld Y. Infection, vaccination, and autoantibodies in chronic fatigue syndrome, cause or coincidence? Ann N Y Acad Sci. 2009;1173(1):600&#x2013;609. doi: 10.1111/j.1749-6632.2009.04799.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2009.04799.x</ArticleId><ArticleId IdType="pubmed">19758205</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiner P, Harrer T, Scheibenbogen C, Lamer S, Schlosser A, Naviaux RK, et al. Human herpesvirus-6 reactivation, mitochondrial fragmentation, and the coordination of antiviral and metabolic phenotypes in myalgic encephalomyelitis/chronic fatigue syndrome. ImmunoHorizons. 2020;4(4):201&#x2013;215. doi: 10.4049/immunohorizons.2000006.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/immunohorizons.2000006</ArticleId><ArticleId IdType="pubmed">32327453</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neal AJ, Hanson MR. The enterovirus theory of disease etiology in myalgic encephalomyelitis/chronic fatigue syndrome: a critical review. Front Med. 2021 doi: 10.3389/fmed.2021.688486.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.688486</ArticleId><ArticleId IdType="pmc">PMC8253308</ArticleId><ArticleId IdType="pubmed">34222292</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia JKS. The role of enterovirus in chronic fatigue syndrome. J Clin Pathol. 2005;58(11):1126&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1770761</ArticleId><ArticleId IdType="pubmed">16254097</ArticleId></ArticleIdList></Reference><Reference><Citation>Bested AC, Marshall LM. Review of myalgic encephalomyelitis/chronic fatigue syndrome: an evidence-based approach to diagnosis and management by clinicians. Rev Environ Health. 2015;30(4):223&#x2013;249. doi: 10.1515/reveh-2015-0026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/reveh-2015-0026</ArticleId><ArticleId IdType="pubmed">26613325</ArticleId></ArticleIdList></Reference><Reference><Citation>Smatti MK, Al-Sadeq DW, Ali NH, Pintus G, Abou-Saleh H, Nasrallah GK. Epstein&#x2013;Barr virus epidemiology, serology, and genetic variability of LMP-1 oncogene among healthy population: an update. Front Oncol. 2018;8(JUN):211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6008310</ArticleId><ArticleId IdType="pubmed">29951372</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Pablos M. CD4+ cytotoxic T cells involved in the development of EBV-associated diseases. Pathogens. 2022;11(8):831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9330826</ArticleId><ArticleId IdType="pubmed">35894054</ArticleId></ArticleIdList></Reference><Reference><Citation>Croia C, Astorri E, Murray-Brown W, Willis A, Brokstad KA, Sutcliffe N, et al. Implication of Epstein&#x2013;Barr virus infection in disease-specific autoreactive B cell activation in ectopic lymphoid structures of Sj&#xf6;gren&#x2019;s syndrome. Arthritis Rheumatol. 2014;66(9):2545&#x2013;2557. doi: 10.1002/ART.38726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ART.38726</ArticleId><ArticleId IdType="pubmed">24891330</ArticleId></ArticleIdList></Reference><Reference><Citation>Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, et al. Dysregulated Epstein&#x2013;Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007;204(12):2899. doi: 10.1084/JEM.20071030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/JEM.20071030</ArticleId><ArticleId IdType="pmc">PMC2118531</ArticleId><ArticleId IdType="pubmed">17984305</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalcante P, Serafini B, Rosicarelli B, Maggi L, Barberis M, Antozzi C, et al. Epstein&#x2013;Barr virus persistence and reactivation in myasthenia gravis thymus. Ann Neurol. 2010;67(6):726&#x2013;738. doi: 10.1002/ANA.21902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ANA.21902</ArticleId><ArticleId IdType="pubmed">20517934</ArticleId></ArticleIdList></Reference><Reference><Citation>Croia C, Serafini B, Bombardieri M, Kelly S, Humby F, Severa M, et al. Epstein&#x2013;Barr virus persistence and infection of autoreactive plasma cells in synovial lymphoid structures in rheumatoid arthritis. Ann Rheum Dis. 2013;72(9):1559&#x2013;1568. doi: 10.1136/annrheumdis-2012-202352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-202352</ArticleId><ArticleId IdType="pubmed">23268369</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucchesi D, Bombardieri M. The role of viruses in autoreactive B cell activation within tertiary lymphoid structures in autoimmune diseases. J Leukoc Biol. 2013;94(6):1191&#x2013;1199. doi: 10.1189/JLB.0413240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/JLB.0413240</ArticleId><ArticleId IdType="pubmed">23812327</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukayama M, Abe H, Kunita A, Shinozaki-Ushiku A, Matsusaka K, Ushiku T, et al. Thirty years of Epstein&#x2013;Barr virus-associated gastric carcinoma. Virchows Arch. 2020;476(3):353&#x2013;365. doi: 10.1007/s00428-019-02724-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00428-019-02724-4</ArticleId><ArticleId IdType="pubmed">31836926</ArticleId></ArticleIdList></Reference><Reference><Citation>Draborg AH, Duus K, Houen G. Epstein&#x2013;Barr virus in systemic autoimmune diseases. Clin Dev Immunol. 2013 doi: 10.1155/2013/535738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/535738</ArticleId><ArticleId IdType="pmc">PMC3766599</ArticleId><ArticleId IdType="pubmed">24062777</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascherio A, Munger KL. Epstein Barr virus. Cham: Springer; 2015. EBV and autoimmunity; pp. 365&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">26424654</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Xie L, Shi F, Tang M, Li Y, Hu J, et al. Targeting the signaling in Epstein&#x2013;Barr virus-associated diseases: mechanism, regulation, and clinical study. Signal Transduct Target Ther. 2021;6(1):1&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7801793</ArticleId><ArticleId IdType="pubmed">33436584</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. Longitudinal analysis reveals high prevalence of Epstein&#x2013;Barr virus associated with multiple sclerosis. Science (80-) 2022;375(6578):296&#x2013;301. doi: 10.1126/science.abj8222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj8222</ArticleId><ArticleId IdType="pubmed">35025605</ArticleId></ArticleIdList></Reference><Reference><Citation>Zdimerova H, Murer A, Engelmann C, Raykova A, Deng Y, Gujer C, et al. Attenuated immune control of Epstein&#x2013;Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA-DR15. Eur J Immunol. 2021;51(1):64&#x2013;75. doi: 10.1002/eji.202048655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202048655</ArticleId><ArticleId IdType="pubmed">32949466</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangalam AK, Taneja V, David CS. HLA class II molecules influence susceptibility vs protection in inflammatory diseases by determining the cytokine profile. J Immunol. 2013;190(2):513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3545203</ArticleId><ArticleId IdType="pubmed">23293357</ArticleId></ArticleIdList></Reference><Reference><Citation>Trowsdale J. The MHC, disease and selection. Immunol Lett. 2011;137(1&#x2013;2):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21262263</ArticleId></ArticleIdList></Reference><Reference><Citation>Bontrop RE, Otting N, De Groot NG, Doxiadis GGM. Major histocompatibility complex class II polymorphisms in primates. Immunol Rev. 1999;167(1):339&#x2013;350. doi: 10.1111/j.1600-065x.1999.tb01403.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065x.1999.tb01403.x</ArticleId><ArticleId IdType="pubmed">10319272</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan ZH, Fan Y, Wang XH, Mao Q, Deng GH, Wang YM. Relationship between HLA-DR gene polymorphisms and outcomes of hepatitis B viral infections: a meta-analysis. World J Gastroenterol. 2012;18(24):3119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3386326</ArticleId><ArticleId IdType="pubmed">22791948</ArticleId></ArticleIdList></Reference><Reference><Citation>Variation in the human genome&#x2014;Google Libros. https://books.google.es/books?hl=es&amp;lr=&amp;id=-3hQJ_VC66UC&amp;oi=fnd&amp;pg=PR5&amp;ots=kXkex_p3hm&amp;sig=5ZOwf2ZZYWzAy9tUQ5bX_PQDUOU&amp;redir_esc=y#v=onepage&amp;q&amp;f=false. Accessed 24 Aug 2022.</Citation></Reference><Reference><Citation>Ehlers B, Spie&#xdf; K, Leendertz F, Peeters M, Boesch C, Gatherer D, et al. Lymphocryptovirus phylogeny and the origins of Epstein&#x2013;Barr virus. J Gen Virol. 2010;91(3):630&#x2013;642. doi: 10.1099/vir.0.017251-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.017251-0</ArticleId><ArticleId IdType="pubmed">19923263</ArticleId></ArticleIdList></Reference><Reference><Citation>Ressing ME, Van Leeuwen D, Verreck FAW, Gomez R, Heemskerk B, Toebes M, et al. Interference with T cell receptor-HLA-DR interactions by Epstein&#x2013;Barr virus gp42 results in reduced T helper cell recognition. Proc Natl Acad Sci USA. 2003;100(20):11583&#x2013;11588. doi: 10.1073/pnas.2034960100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2034960100</ArticleId><ArticleId IdType="pmc">PMC208801</ArticleId><ArticleId IdType="pubmed">14504389</ArticleId></ArticleIdList></Reference><Reference><Citation>Trier N, Izarzugaza J, Chailyan A, Marcatili P, Houen G. Human MHC-II with shared epitope motifs are optimal Epstein&#x2013;Barr virus glycoprotein 42 ligands&#x2014;relation to rheumatoid arthritis. Int J Mol Sci. 2018;19(1):317. doi: 10.3390/ijms19010317.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19010317</ArticleId><ArticleId IdType="pmc">PMC5796260</ArticleId><ArticleId IdType="pubmed">29361739</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Bu W, Gabriel E, Aguilar F, Hoshino Y, Miyadera H, et al. HLA-DQ &#x3b2;1 alleles associated with Epstein&#x2013;Barr virus (EBV) infectivity and EBV gp42 binding to cells. JCI Insight. 2017;2(4):e85687. doi: 10.1172/jci.insight.85687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.85687</ArticleId><ArticleId IdType="pmc">PMC5313076</ArticleId><ArticleId IdType="pubmed">28239644</ArticleId></ArticleIdList></Reference><Reference><Citation>Spriggs MK, Armitage RJ, Comeau MR, Strockbine L, Farrah T, Macduff B, et al. The extracellular domain of the Epstein&#x2013;Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation. J Virol. 1996;70(8):5557&#x2013;5563. doi: 10.1128/JVI.70.8.5557-5563.1996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.70.8.5557-5563.1996</ArticleId><ArticleId IdType="pmc">PMC190515</ArticleId><ArticleId IdType="pubmed">8764069</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung CS, Haigh TA, Mackay LK, Rickinson AB, Taylor GS. Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display. Proc Natl Acad Sci USA. 2010;107(5):2165&#x2013;2170. doi: 10.1073/pnas.0909448107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0909448107</ArticleId><ArticleId IdType="pmc">PMC2836662</ArticleId><ArticleId IdType="pubmed">20133861</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksen W. The spread of EBV to ectopic lymphoid aggregates may be the final common pathway in the pathogenesis of ME/CFS. Med Hypotheses. 2017;102:8&#x2013;15. doi: 10.1016/j.mehy.2017.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2017.02.011</ArticleId><ArticleId IdType="pubmed">28478837</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitzalis C, Jones GW, Bombardieri M, Jones SA. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev Immunol. 2014;14(7):447&#x2013;462. doi: 10.1038/nri3700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3700</ArticleId><ArticleId IdType="pubmed">24948366</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo A, Bombardieri M, Humby F, Pitzalis C. Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis: from inflammation to autoimmunity and tissue damage/remodeling. Immunol Rev. 2010;233(1):267&#x2013;285. doi: 10.1111/J.0105-2896.2009.00861.X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/J.0105-2896.2009.00861.X</ArticleId><ArticleId IdType="pubmed">20193005</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Monta&#xf1;&#xe9;s M, Alari-Pahissa E, Sintes J, Mart&#xed;nez-Rodr&#xed;guez JE, Muntasell A, L&#xf3;pez-Botet M. Antibody-dependent NK cell activation differentially targets EBV-infected cells in lytic cycle and bystander B lymphocytes bound to viral antigen-containing particles. J Immunol. 2017;199(2):656&#x2013;665. doi: 10.4049/jimmunol.1601574.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1601574</ArticleId><ArticleId IdType="pubmed">28630095</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatton OL, Harris-Arnold A, Schaffert S, Krams SM, Martinez OM. The interplay between Epstein&#x2013;Barr virus and B lymphocytes: implications for infection, immunity, and disease. Immunol Res. 2014;58(2&#x2013;3):268&#x2013;276. doi: 10.1007/s12026-014-8496-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-014-8496-1</ArticleId><ArticleId IdType="pmc">PMC4199828</ArticleId><ArticleId IdType="pubmed">24619311</ArticleId></ArticleIdList></Reference><Reference><Citation>Wosen JE, Mukhopadhyay D, MacAubas C, Mellins ED. Epithelial MHC class II expression and its role in antigen presentation in the gastrointestinal and respiratory tracts. Front Immunol. 2018;9(SEP):2144. doi: 10.3389/fimmu.2018.02144.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02144</ArticleId><ArticleId IdType="pmc">PMC6167424</ArticleId><ArticleId IdType="pubmed">30319613</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-&#x3b3;: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75(2):163&#x2013;189. doi: 10.1189/JLB.0603252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/JLB.0603252</ArticleId><ArticleId IdType="pubmed">14525967</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwakiri D, Takada K. Role of EBERs in the pathogenesis of EBV infection. Adv Cancer Res. 2010;107:119&#x2013;136. doi: 10.1016/S0065-230X(10)07004-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0065-230X(10)07004-1</ArticleId><ArticleId IdType="pubmed">20399962</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Lin Y, Xiao H, Xing S, Chen H, Chi P, et al. Epstein&#x2013;Barr virus infection induces indoleamine 2,3-dioxygenase expression in human monocyte-derived macrophages through p38/mitogen-activated protein kinase and NF-&#x3ba;B pathways: impairment in T cell functions. J Virol. 2014;88(12):6660&#x2013;6671. doi: 10.1128/JVI.03678-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03678-13</ArticleId><ArticleId IdType="pmc">PMC4054364</ArticleId><ArticleId IdType="pubmed">24696473</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzartos JS, Khan G, Vossenkamper A, Cruz-Sadaba M, Lonardi S, Sefia E, et al. Association of innate immune activation with latent Epstein&#x2013;Barr virus in active MS lesions. Neurology. 2012;78(1):15&#x2013;23. doi: 10.1212/WNL.0b013e31823ed057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31823ed057</ArticleId><ArticleId IdType="pubmed">22156987</ArticleId></ArticleIdList></Reference><Reference><Citation>Glaser R, Litsky ML, Padgett DA, Baiocchi RA, Yang EV, Chen M, et al. EBV-encoded dUTPase induces immune dysregulation: implications for the pathophysiology of EBV-associated disease. Virology. 2006;346(1):205&#x2013;218. doi: 10.1016/j.virol.2005.10.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2005.10.034</ArticleId><ArticleId IdType="pubmed">16321417</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerner AM, Beqaj S. A paradigm linking herpesvirus immediate-early gene expression apoptosis and myalgic encephalomyelitis chronic fatigue syndrome. Virus Adapt Treat. 2011;3(1):19&#x2013;24. doi: 10.2147/VAAT.S15105.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/VAAT.S15105</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumforth KRN, Birgersdotter A, Reynolds GM, Wei W, Kapatai G, Flavell JR, et al. Expression of the Epstein&#x2013;Barr virus-encoded Epstein&#x2013;Barr virus nuclear antigen 1 in Hodgkin&#x2019;s lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol. 2008;173(1):195&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2438297</ArticleId><ArticleId IdType="pubmed">18502823</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, He C, Wu J, Yang D, Yi W. Epstein Barr virus encodes miRNAs to assist host immune escape. J Cancer. 2020;11(8):2091&#x2013;2100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7052931</ArticleId><ArticleId IdType="pubmed">32127936</ArticleId></ArticleIdList></Reference><Reference><Citation>Burdin N, P&#xe9;ronne C, Banchereau J, Rousset F. Epstein&#x2013;Barr virus transformation induces B lymphocytes to produce human interleukin 10. J Exp Med. 1993;177(2):295&#x2013;304. doi: 10.1084/jem.177.2.295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.177.2.295</ArticleId><ArticleId IdType="pmc">PMC2190909</ArticleId><ArticleId IdType="pubmed">8381152</ArticleId></ArticleIdList></Reference><Reference><Citation>Taneja V. Sex hormones determine immune response. Front Immunol. 2018;9:1931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119719</ArticleId><ArticleId IdType="pubmed">30210492</ArticleId></ArticleIdList></Reference><Reference><Citation>Athreya BH, Pletcher J, Zulian F, Weiner DB, Williams WV. Subset-specific effects of sex hormones and pituitary gonadotropins on human lymphocyte proliferation in vitro. Clin Immunol Immunopathol. 1993;66(3):201&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">8094329</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol. 2014;35(3):347&#x2013;369. doi: 10.1016/j.yfrne.2014.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yfrne.2014.04.004</ArticleId><ArticleId IdType="pubmed">24793874</ArticleId></ArticleIdList></Reference><Reference><Citation>Toussirot E, Roudier J. Pathophysiological links between rheumatoid arthritis and the Epstein&#x2013;Barr virus: an update. Jt Bone Spine. 2007;74(5):418&#x2013;426. doi: 10.1016/j.jbspin.2007.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbspin.2007.05.001</ArticleId><ArticleId IdType="pubmed">17625943</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazbek MA, de Barros-Mazon S, Rossi CL, Londe AC, Costallat LTL, B&#xe9;rtolo MB. Association analysis of anti-Epstein&#x2013;Barr nuclear antigen-1 antibodies, anti-cyclic citrullinated peptide antibodies, the shared epitope and smoking status in Brazilian patients with rheumatoid arthritis. Clinics. 2011;66(8):1401&#x2013;1406. doi: 10.1590/s1807-59322011000800016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s1807-59322011000800016</ArticleId><ArticleId IdType="pmc">PMC3161219</ArticleId><ArticleId IdType="pubmed">21915491</ArticleId></ArticleIdList></Reference><Reference><Citation>You L, Jin S, Zhu L, Qian W. Autophagy, autophagy-associated adaptive immune responses and its role in hematologic malignancies. Oncotarget. 2017;8(7):12374&#x2013;12388. doi: 10.18632/oncotarget.13583.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.13583</ArticleId><ArticleId IdType="pmc">PMC5355352</ArticleId><ArticleId IdType="pubmed">27902471</ArticleId></ArticleIdList></Reference><Reference><Citation>Trier NH, Holm BE, Heiden J, Slot O, Locht H, Lindegaard H, et al. Antibodies to a strain-specific citrullinated Epstein&#x2013;Barr virus peptide diagnoses rheumatoid arthritis. Sci Rep. 2018;8(1):3684. doi: 10.1038/s41598-018-22058-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-22058-6</ArticleId><ArticleId IdType="pmc">PMC5829227</ArticleId><ArticleId IdType="pubmed">29487382</ArticleId></ArticleIdList></Reference><Reference><Citation>Oertelt-Prigione S. Immunology and the menstrual cycle. Autoimmun Rev. 2012;11(6&#x2013;7):A486&#x2013;A492.</Citation><ArticleIdList><ArticleId IdType="pubmed">22155200</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashwini Rani S, Suragimath G, Rajmane V, Rajmane Y. Prevalence of recurrent herpes labialis in western Maharashtra. J Oral Maxillofac Pathol. 2021;25(1):51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8272484</ArticleId><ArticleId IdType="pubmed">34349411</ArticleId></ArticleIdList></Reference><Reference><Citation>Menegatti J, Schub D, Sch&#xe4;fer M, Gr&#xe4;sser FA, Ruprecht K. HLA-DRB1*15:01 is a co-receptor for Epstein&#x2013;Barr virus, linking genetic and environmental risk factors for multiple sclerosis. Eur J Immunol. 2021;51(9):2348&#x2013;2350. doi: 10.1002/eji.202149179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202149179</ArticleId><ArticleId IdType="pubmed">34019695</ArticleId></ArticleIdList></Reference><Reference><Citation>McShane MP, Mullen MM, Haan KM, Jardetzky TS, Longnecker R. Mutational analysis of the HLA class II interaction with Epstein&#x2013;Barr virus glycoprotein 42. J Virol. 2003;77(13):7655&#x2013;7662. doi: 10.1128/jvi.77.13.7655-7662.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.77.13.7655-7662.2003</ArticleId><ArticleId IdType="pmc">PMC164790</ArticleId><ArticleId IdType="pubmed">12805465</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullen MM, Haan KM, Longnecker R, Jardetzky TS. Structure of the Epstein&#x2013;Barr virus gp42 protein bound to the MHC class II receptor HLA-DR1. Mol Cell. 2002;9(2):375&#x2013;385. doi: 10.1016/s1097-2765(02)00465-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1097-2765(02)00465-3</ArticleId><ArticleId IdType="pubmed">11864610</ArticleId></ArticleIdList></Reference><Reference><Citation>Haan KM, Longnecker R. Coreceptor restriction within the HLA-DQ locus for Epstein&#x2013;Barr virus infection. Proc Natl Acad Sci USA. 2000;97(16):9252&#x2013;9257. doi: 10.1073/pnas.160171697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.160171697</ArticleId><ArticleId IdType="pmc">PMC16854</ArticleId><ArticleId IdType="pubmed">10908662</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;nemann JD, Jel&#x10d;i&#x107; I, Roberts S, Lutterotti A, Tackenberg B, Martin R, et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-&#x3b3; and IL-2. J Exp Med. 2008;205(8):1763&#x2013;1773. doi: 10.1084/jem.20072397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20072397</ArticleId><ArticleId IdType="pmc">PMC2525578</ArticleId><ArticleId IdType="pubmed">18663124</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav P, Tran H, Ebegbe R, Gottlieb P, Wei H, Lewis RH, et al. Antibodies elicited in response to EBNA-1 may cross- react with dsDNA. PLoS ONE. 2011;6(1):e14488. doi: 10.1371/journal.pone.0014488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0014488</ArticleId><ArticleId IdType="pmc">PMC3014975</ArticleId><ArticleId IdType="pubmed">21245919</ArticleId></ArticleIdList></Reference><Reference><Citation>Poole BD, Scofield RH, Harley JB, James JA. Epstein&#x2013;Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity. 2006;39(1):63&#x2013;70. doi: 10.1080/08916930500484849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916930500484849</ArticleId><ArticleId IdType="pubmed">16455583</ArticleId></ArticleIdList></Reference><Reference><Citation>Poole BD, Gross T, Maier S, Harley JB, James JA. Lupus-like autoantibody development in rabbits and mice after immunization with EBNA-1 fragments. J Autoimmun. 2008;31(4):362&#x2013;371. doi: 10.1016/j.jaut.2008.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2008.08.007</ArticleId><ArticleId IdType="pmc">PMC2852321</ArticleId><ArticleId IdType="pubmed">18849143</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray PF, Luka J, Bray PF, Culp KW, Schlight JP. Antibodies against Epstein&#x2013;Barr nuclear antigen (EBNA) in multiple sclerosis CSF and two pentapepfide seauence identities between EBNA and myelin basic protein. Neurology. 1992;42(9):1798&#x2013;1804. doi: 10.1212/wnl.42.9.1798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.42.9.1798</ArticleId><ArticleId IdType="pubmed">1381067</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahan SM, Wherry EJ, Zajac AJ. T cell exhaustion during persistent viral infections. Virology. 2015;479&#x2013;480:180&#x2013;193. doi: 10.1016/j.virol.2014.12.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2014.12.033</ArticleId><ArticleId IdType="pmc">PMC4424083</ArticleId><ArticleId IdType="pubmed">25620767</ArticleId></ArticleIdList></Reference><Reference><Citation>Visvabharathy L, Hanson B, Orban Z, Lim PH, Palacio NM, Jain R, et al. Neuro-COVID long-haulers exhibit broad dysfunction in T cell memory generation and responses to vaccination. medRxiv. 2021 doi: 10.1101/2021.08.08.21261763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.08.08.21261763</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207(10):2187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947065</ArticleId><ArticleId IdType="pubmed">20819927</ArticleId></ArticleIdList></Reference><Reference><Citation>Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJD, Suresh M, Altman JD, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998;188(12):2205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2212420</ArticleId><ArticleId IdType="pubmed">9858507</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Duan Y, Cheng S, Chen Y, Hu Y, Zhang L, et al. EBV-encoded RNA via TLR3 induces inflammation in nasopharyngeal carcinoma. Oncotarget. 2015;6(27):24291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4695186</ArticleId><ArticleId IdType="pubmed">26172457</ArticleId></ArticleIdList></Reference><Reference><Citation>Park GB, Hur DY, Kim YS, Lee HK, Yang JW, Kim D. TLR3/TRIF signalling pathway regulates IL-32 and IFN-&#x3b2; secretion through activation of RIP-1 and TRAF in the human cornea. J Cell Mol Med. 2015;19(5):1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4420606</ArticleId><ArticleId IdType="pubmed">25754842</ArticleId></ArticleIdList></Reference><Reference><Citation>Martorelli D, Muraro E, Merlo A, Turrini R, Fa&#xe8; DA, Rosato A, et al. Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein&#x2013;Barr-virus-driven disorders. Clin Dev Immunol. 2012 doi: 10.1155/2012/931952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/931952</ArticleId><ArticleId IdType="pmc">PMC3272797</ArticleId><ArticleId IdType="pubmed">22319542</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai K-Y, Chou Y-C, Lin J-H, Liu Y, Lin K-M, Doong S-L, et al. Maintenance of Epstein&#x2013;Barr virus latent status by a novel mechanism, latent membrane protein 1-induced interleukin-32, via the protein kinase C&#x3b4; pathway. J Virol. 2015;89(11):5968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4442432</ArticleId><ArticleId IdType="pubmed">25810549</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoi T, Miyawaki T, Yachie A, Kato K, Kasahara Y, Taniguchi N. Epstein&#x2013;Barr virus-immortalized B cells produce IL-6 as an autocrine growth factor. Immunology. 1990;70(1):100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1384088</ArticleId><ArticleId IdType="pubmed">2162322</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghetti P, Saleri R, Mocchegiani E, Corradi A, Martelli P. Infection, immunity and the neuroendocrine response. Vet Immunol Immunopathol. 2009;130(3):141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112574</ArticleId><ArticleId IdType="pubmed">19261335</ArticleId></ArticleIdList></Reference><Reference><Citation>Muraro E, Merlo A, Martorelli D, Cangemi M, Santa SD, Dolcetti R, et al. Fighting viral infections and virus-driven tumors with cytotoxic CD4+ T cells. Front Immunol. 2017;8(FEB):197. doi: 10.3389/fimmu.2017.00197.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00197</ArticleId><ArticleId IdType="pmc">PMC5327441</ArticleId><ArticleId IdType="pubmed">28289418</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Perdomo MF, Kantele A, Hedman L, Hedman K, Franssila R. Granzyme B mediated function of Parvovirus B19-specific CD4+ T cells. Clin Transl Immunol. 2015;4(7):e39. doi: 10.1038/cti.2015.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cti.2015.13</ArticleId><ArticleId IdType="pmc">PMC4524951</ArticleId><ArticleId IdType="pubmed">26246896</ArticleId></ArticleIdList></Reference><Reference><Citation>Walton S, Mandaric S, Oxenius A. CD4 T cell responses in latent and chronic viral infections. Front Immunol. 2013;4(MAY):105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651995</ArticleId><ArticleId IdType="pubmed">23717308</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribeiro FM, Gomez VE, Albuquerque EMN, Klumb EM, Shoenfeld Y. Lupus and leprosy: beyond the coincidence. Immunol Res. 2014;61(1&#x2013;2):160&#x2013;163. doi: 10.1007/s12026-014-8596-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-014-8596-y</ArticleId><ArticleId IdType="pubmed">25412733</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinov KN, Emil SN, Barry M, Kellie S, Tzamaloukas AH. Glomerular disease in patients with infectious processes developing antineutrophil cytoplasmic antibodies. ISRN Nephrol. 2013;2013:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4045435</ArticleId><ArticleId IdType="pubmed">24959541</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermann J, Demel U, St&#xfc;nzner D, Daghofer E, Tilz G, Graninger W. Clinical interpretation of antineutrophil cytoplasmic antibodies: parvovirus B19 infection as a pitfall. Ann Rheum Dis. 2005;64(4):641&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1755429</ArticleId><ArticleId IdType="pubmed">15485998</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu P, Lin S, Wei L, Shang W. Antineutrophil cytoplasmic antibody-associated vasculitis associated with Epstein&#x2013;Barr virus infection: a case report and review of the literature. Infection. 2014;42(3):591&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">24610176</ArticleId></ArticleIdList></Reference><Reference><Citation>Noonan TP, Konstantinov KN, Echevarria L. Epstein&#x2013;Barr virus reactivation induced myeloperoxidase-specific antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis. BMJ Case Rep CP. 2021;14(10):e245059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8499269</ArticleId><ArticleId IdType="pubmed">34620637</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayet WJ, Hermann E, Kiefer B, Lehmann H, Manns M, B&#xfc;schenfelde KHMZ. In vitro production of anti-neutrophilocyte-cytoplasm-antibodies (Anca) by Epstein&#x2013;Barr virus-transformed b-cell lines in Wegener&#x2019;s granulomatosis. Autoimmunity. 2009;11(1):13&#x2013;19. doi: 10.3109/08916939108994703.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08916939108994703</ArticleId><ArticleId IdType="pubmed">1725964</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariza ME, Cox B, Martinez B, Mena-Palomo I, Zarate GJ, Williams MV. Viral dUTPases: modulators of innate immunity. Biomolecules. 2022;12(2):227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8961515</ArticleId><ArticleId IdType="pubmed">35204728</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x160;estan M, Marinovi&#x107; S, Kavazovi&#x107; I, Cekinovi&#x107; &#x110;, Wueest S, Turk Wensveen T, et al. Virus-induced interferon-&#x3b3; causes insulin resistance in skeletal muscle and derails glycemic control in obesity. Immunity. 2018;49(1):164&#x2013;177.e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29958802</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan K, MacIver NJ. Viral infection &#x201c;interferes&#x201d; with glucose tolerance. Immunity. 2018;49(1):6&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">30021147</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x160;estan M, Beni&#x107; A, Mikasinovi&#x107; S, Konrad D, Wueest S, Turk Wensveen T, et al. Type 2 diabetes impairs antiviral immunity by preventing the induction of fasting metabolism. Diabetes Technol Ther. 2022;11:A46. doi: 10.1177/2164957X221096590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2164957X221096590</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccaluga PP, Weber A, Ambrosio MR, Ahmed Y, Leoncini L. Epstein&#x2013;Barr virus-induced metabolic rearrangements in human B-cell lymphomas. Front Microbiol. 2018;9(JUN):1233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6002739</ArticleId><ArticleId IdType="pubmed">29937761</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahdi M, Almehman B, Nassan S, Binyahib S. Pancreatic insulinoma causing hypoglycemic episodes. J Pediatr Surg Case Rep. 2020;57:101466.</Citation></Reference><Reference><Citation>Gandhi K. Approach to hypoglycemia in infants and children. Transl Pediatr. 2017;6(4):408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5682370</ArticleId><ArticleId IdType="pubmed">29184821</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis MR, Shamoon H. Deficient counterregulatory hormone responses during hypoglycemia in a patient with insulinoma. J Clin Endocrinol Metab. 1991;72(4):788&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pubmed">2005202</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Zhou W, Fang B, Lu W, Loro E, Damle M, et al. Dissociation of muscle insulin sensitivity from exercise endurance in mice by HDAC3. Nat Med. 2017;23(2):223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5540654</ArticleId><ArticleId IdType="pubmed">27991918</ArticleId></ArticleIdList></Reference><Reference><Citation>Nesti L, Pugliese NR, Sciuto P, Natali A. Type 2 diabetes and reduced exercise tolerance: a review of the literature through an integrated physiology approach. Cardiovasc Diabetol. 2020;19(1):1&#x2013;17. doi: 10.1186/s12933-020-01109-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-020-01109-1</ArticleId><ArticleId IdType="pmc">PMC7487838</ArticleId><ArticleId IdType="pubmed">32891175</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones K, Rivera C, Sgadari C, Franklin J, Max EE, Bhatia K, et al. Infection of human endothelial cells with Epstein&#x2013;Barr virus. J Exp Med. 1995;182(5):1213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2192185</ArticleId><ArticleId IdType="pubmed">7595192</ArticleId></ArticleIdList></Reference><Reference><Citation>Merz KE, Thurmond DC. Role of skeletal muscle in insulin resistance and glucose uptake. Compr Physiol. 2020;10(3):785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8074531</ArticleId><ArticleId IdType="pubmed">32940941</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes-Canteli M, Paul J, Norris EH, Bronstein R, Ahn HJ, Zamolodchikov D, et al. Fibrinogen and &#x3b2;-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer&#x2019;s disease. Neuron. 2010;66(5):695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895773</ArticleId><ArticleId IdType="pubmed">20547128</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaelides M, Stover NB, Francis PJ, Weleber RG. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol. 2011;129(1):30&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">21220626</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadeja RN, Martin PM. Oxidative stress and inflammation in retinal degeneration. Antioxidants. 2021;10(5):790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8156590</ArticleId><ArticleId IdType="pubmed">34067655</ArticleId></ArticleIdList></Reference><Reference><Citation>Bornstein SR, Engeland WC, Ehrhart-Bornstein M, Herman JP. Dissociation of ACTH and glucocorticoids. Trends Endocrinol Metab. 2008;19(5):175&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">18394919</ArticleId></ArticleIdList></Reference><Reference><Citation>Reincke M, Heppner C, Petzke F, Allolio B, Arlt W, Mbulamberi D, et al. Impairment of adrenocortical function associated with increased plasma tumor necrosis factor-alpha and interleukin-6 concentrations in African trypanosomiasis. NeuroImmunoModulation. 1994;1(1):14&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">8528879</ArticleId></ArticleIdList></Reference><Reference><Citation>Roque S, Correia-Neves M, Mesquita AR, Palha JA, Sousa N. Interleukin-10: a key cytokine in depression? Cardiovasc Psychiatry Neurol. 2009;2009:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775686</ArticleId><ArticleId IdType="pubmed">19936104</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Ahmad A, Jones JF, Dolcetti R, Vaccher E, Prasad U, et al. elevated serum transforming growth factor &#x3b2;1 levels in Epstein&#x2013;Barr virus-associated diseases and their correlation with virus-specific immunoglobulin A (IgA) and IgM. J Virol. 2000;74(5):2443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC111728</ArticleId><ArticleId IdType="pubmed">10666277</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunne PJ, Rowan AG, Fletcher JM, Mills KHG. Regulatory T cells and clinical application. New York: Springer; 2008. IL-10 and TGF-&#x3b2;-producing regulatory T cells in infection; pp. 423&#x2013;453.</Citation></Reference><Reference><Citation>Nassoro DD, Mkhoi ML, Sabi I, Meremo AJ, Lawala PS, Mwakyula IH. Adrenal insufficiency: a forgotten diagnosis in HIV/AIDS patients in developing countries. Int J Endocrinol. 2019 doi: 10.1155/2019/2342857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/2342857</ArticleId><ArticleId IdType="pmc">PMC6612386</ArticleId><ArticleId IdType="pubmed">31341472</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrchen JM, Roth J, Barczyk-Kahlert K. More than suppression: glucocorticoid action on monocytes and macrophages. Front Immunol. 2019;10(AUG):2028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6718555</ArticleId><ArticleId IdType="pubmed">31507614</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong ACN, Vogt MC, Hill AS, Br&#xfc;ning JC, Zeltser LM. Central insulin signaling modulates hypothalamus&#x2013;pituitary&#x2013;adrenal axis responsiveness. Mol Metab. 2015;4(2):83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4314547</ArticleId><ArticleId IdType="pubmed">25685696</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain K, Hindmarsh P, Aynsley-Green A. Neonates with symptomatic hyperinsulinemic hypoglycemia generate inappropriately low serum cortisol counterregulatory hormonal responses. J Clin Endocrinol Metab. 2003;88(9):4342&#x2013;4347.</Citation><ArticleIdList><ArticleId IdType="pubmed">12970308</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed S, Soliman A, De Sanctis V, Alyafie F, Alaaraj N, Hamed N, et al. Defective cortisol secretion in response to spontaneous hypoglycemia but normal cortisol response to ACTH stimulation in neonates with hyperinsulinemic hypoglycemia (HH) Acta Bio Medica Atenei Parm. 2021;92(2):2021182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8182578</ArticleId><ArticleId IdType="pubmed">33988135</ArticleId></ArticleIdList></Reference><Reference><Citation>Layunta E, Buey B, Mesonero JE, Latorre E. Crosstalk between intestinal serotonergic system and pattern recognition receptors on the microbiota&#x2013;gut&#x2013;brain axis. Front Endocrinol. 2021;12:1379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8607755</ArticleId><ArticleId IdType="pubmed">34819919</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendoza C, Matheus N, Latorre E, Castro M, Mesonero JE, Alcalde AI. Toll-like receptor 3 activation affects serotonin transporter activity and expression in human enterocyte-like Caco-2 cells. Cell Physiol Biochem. 2012;30(1):187&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">22759966</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwakiri D, Zhou L, Samanta M, Matsumoto M, Ebihara T, Seya T, et al. Epstein&#x2013;Barr virus (EBV)&#x2013;encoded small RNA is released from EBV-infected cells and activates signaling from toll-like receptor 3. J Exp Med. 2009;206(10):2091&#x2013;2099. doi: 10.1084/jem.20081761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20081761</ArticleId><ArticleId IdType="pmc">PMC2757889</ArticleId><ArticleId IdType="pubmed">19720839</ArticleId></ArticleIdList></Reference><Reference><Citation>Latorre E, Layunta E, Grasa L, Castro M, Pardo J, Gom&#xf3;lln F, et al. Intestinal serotonin transporter inhibition by toll-like receptor 2 activation. A feedback modulation. PLoS ONE. 2016;11(12):e0169303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5199115</ArticleId><ArticleId IdType="pubmed">28033388</ArticleId></ArticleIdList></Reference><Reference><Citation>Schw&#xf6;rer H, Ramadori G. Autoreceptors can modulate 5-hydroxytryptamine release from porcine and human small intestine in vitro. Naunyn-Schmiedeberg&#x2019;s Arch Pharmacol. 1998;357(5):548&#x2013;552. doi: 10.1007/PL00005206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/PL00005206</ArticleId><ArticleId IdType="pubmed">9650808</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry N, Margolis KG. Serotonergic mechanisms regulating the GI tract: experimental evidence and therapeutic relevance. Handb Exp Pharmacol. 2017;239:319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5526216</ArticleId><ArticleId IdType="pubmed">28035530</ArticleId></ArticleIdList></Reference><Reference><Citation>Ormsbee HS, Fondacaro JD. Action of serotonin on the gastrointestinal tract. Proc Soc Exp Biol Med. 1985;178(3):333&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">3919396</ArticleId></ArticleIdList></Reference><Reference><Citation>Browning KN. Role of central vagal 5-HT3 receptors in gastrointestinal physiology and pathophysiology. Front Neurosci. 2015;9(OCT):413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4625078</ArticleId><ArticleId IdType="pubmed">26578870</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebermeyer T, Cognasse F, Berthelot P, Mismetti P, Garraud O, Hamzeh-cognasse H. Platelet innate immune receptors and TLRs: a double-edged sword. Int J Mol Sci. 2021;22(15):7894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8347377</ArticleId><ArticleId IdType="pubmed">34360659</ArticleId></ArticleIdList></Reference><Reference><Citation>Foley S, Garsed K, Singh G, Duroudier NP, Swan C, Hall IP, et al. Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation. Gastroenterology. 2011;140(5):1434&#x2013;1443.</Citation><ArticleIdList><ArticleId IdType="pubmed">21315720</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercado CP, Kilic F. Molecular mechanisms of SERT in platelets: regulation of plasma serotonin levels. Mol Interv. 2010;10(4):231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965611</ArticleId><ArticleId IdType="pubmed">20729489</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K, Oh CM, Ohara-Imaizumi M, Park S, Namkung J, Yadav VK, et al. Functional role of serotonin in insulin secretion in a diet-induced insulin-resistant state. Endocrinology. 2015;156(2):444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4298319</ArticleId><ArticleId IdType="pubmed">25426873</ArticleId></ArticleIdList></Reference><Reference><Citation>Alma&#xe7;a J, Molina J, Menegaz D, Pronin AN, Tamayo A, Slepak V, et al. Human beta cells produce and release serotonin to inhibit glucagon secretion from alpha cells. Cell Rep. 2016;17(12):3281&#x2013;3291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5217294</ArticleId><ArticleId IdType="pubmed">28009296</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh CM, Park S, Kim H. Serotonin as a new therapeutic target for diabetes mellitus and obesity. Diabetes Metab J. 2016;40(2):89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4853228</ArticleId><ArticleId IdType="pubmed">27126880</ArticleId></ArticleIdList></Reference><Reference><Citation>Noda M, Ifuku M, Hossain MS, Katafuchi T. Glial activation and expression of the serotonin transporter in chronic fatigue syndrome. Front Psychiatry. 2018;9:589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250825</ArticleId><ArticleId IdType="pubmed">30505285</ArticleId></ArticleIdList></Reference><Reference><Citation>Katafuchi T, Kondo T, Take S, Yoshimura M. Brain cytokines and the 5-HT system during poly I:C-induced fatigue. Ann N Y Acad Sci. 2006;1088(1):230&#x2013;237. doi: 10.1196/annals.1366.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1366.020</ArticleId><ArticleId IdType="pubmed">17192569</ArticleId></ArticleIdList></Reference><Reference><Citation>Malynn S, Campos-Torres A, Moynagh P, Haase J. The pro-inflammatory cytokine TNF-&#x3b1; regulates the activity and expression of the serotonin transporter (SERT) in astrocytes. Neurochem Res. 2013;38(4):694&#x2013;704. doi: 10.1007/s11064-012-0967-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-012-0967-y</ArticleId><ArticleId IdType="pubmed">23338678</ArticleId></ArticleIdList></Reference><Reference><Citation>Korte-Bouws GAH, van Heesch F, Westphal KGC, Ankersmit LMJ, van Oosten EM, G&#xfc;nt&#xfc;rk&#xfc;n O, et al. Bacterial lipopolysaccharide increases serotonin metabolism in both medial prefrontal cortex and nucleus accumbens in male wild type rats, but not in serotonin transporter knockout rats. Pharmaceuticals. 2018;11(3):66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6160917</ArticleId><ArticleId IdType="pubmed">29976854</ArticleId></ArticleIdList></Reference><Reference><Citation>Ping F, Shang J, Zhou J, Zhang H, Zhang L. 5-HT1A receptor and apoptosis contribute to interferon-&#x3b1;-induced &#x201c;depressive-like&#x201d; behavior in mice. Neurosci Lett. 2012;514(2):173&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">22414862</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv J, Liu F. The role of serotonin beyond the central nervous system during embryogenesis. Front Cell Neurosci. 2017;11:74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5346549</ArticleId><ArticleId IdType="pubmed">28348520</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesch KP, Sohnle K, Poten B, Schoellnhammer G, Rupprecht R, Schulte HM. Corticotropin and cortisol secretion after central 5-hydroxytryptamine-1A (5-HT1A) receptor activation: effects of 5-HT receptor and &#x3b2;-adrenoceptor antagonists. J Clin Endocrinol Metab. 1990;70(3):670&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">1968468</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR. Interferon-&#x3b3; and tumor necrosis factor-&#x3b1; synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol. 2005;166(2):409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1237049</ArticleId><ArticleId IdType="pubmed">15681825</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma L, Riva A. Intestinal barrier function in health and disease&#x2014;any role of SARS-CoV-2? Microorganisms. 2020;8(11):1744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7694956</ArticleId><ArticleId IdType="pubmed">33172188</ArticleId></ArticleIdList></Reference><Reference><Citation>Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol. 2007;3(2):112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3099351</ArticleId><ArticleId IdType="pubmed">21960820</ArticleId></ArticleIdList></Reference><Reference><Citation>Raithel M, Weidenhiller M, Hagel AFK, Hetterich U, Neurath MF, Konturek PC. The malabsorption of commonly occurring mono and disaccharides: levels of investigation and differential diagnoses. Dtsch Arztebl Int. 2013;110(46):775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855820</ArticleId><ArticleId IdType="pubmed">24300825</ArticleId></ArticleIdList></Reference><Reference><Citation>Boga JA, Coto-Montes A, Rosales-Corral SA, Tan DX, Reiter RJ. Beneficial actions of melatonin in the management of viral infections: a new use for this &#x201c;molecular handyman&#x201d;? Rev Med Virol. 2012;22(5):323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7169144</ArticleId><ArticleId IdType="pubmed">22511571</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo J, Bellot G, Pervaiz S, Alonso S. Mitochondria-mediated oxidative stress during viral infection. Trends Microbiol. 2022;30(7):679&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pubmed">35063304</ArticleId></ArticleIdList></Reference><Reference><Citation>Arfin S, Jha NK, Jha SK, Kesari KK, Ruokolainen J, Roychoudhury S, et al. Oxidative stress in cancer cell metabolism. Antioxidants. 2021;10(5):642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8143540</ArticleId><ArticleId IdType="pubmed">33922139</ArticleId></ArticleIdList></Reference><Reference><Citation>Kgatle MM, Spearman CW, Kalla AA, Hairwadzi HN. DNA oncogenic virus-induced oxidative stress, genomic damage, and aberrant epigenetic alterations. Oxid Med Cell Longev. 2017 doi: 10.1155/2017/3179421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/3179421</ArticleId><ArticleId IdType="pmc">PMC5504953</ArticleId><ArticleId IdType="pubmed">28740569</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Li Y, Li H, Shi F, Xie L, Zhao L, et al. Targeting Epstein&#x2013;Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy. Theranostics. 2020;10(26):11921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7667690</ArticleId><ArticleId IdType="pubmed">33204320</ArticleId></ArticleIdList></Reference><Reference><Citation>Strycharz-Dudziak M, Kie&#x142;czykowska M, Drop B, &#x15a;wi&#x105;tek &#x141;, Kliszczewska E, Musik I, et al. Total antioxidant status (TAS), superoxide dismutase (SOD), and glutathione peroxidase (GPx) in oropharyngeal cancer associated with EBV infection. Oxid Med Cell Longev. 2019 doi: 10.1155/2019/5832410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/5832410</ArticleId><ArticleId IdType="pmc">PMC6644273</ArticleId><ArticleId IdType="pubmed">31360295</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Nagy N, Masucci MG. The Epstein&#x2013;Barr virus nuclear antigen-1 upregulates the cellular antioxidant defense to enable B-cell growth transformation and immortalization. Oncogene. 2020;39(3):603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6962091</ArticleId><ArticleId IdType="pubmed">31511648</ArticleId></ArticleIdList></Reference><Reference><Citation>Morii T, Ohno Y, Hirose H, Kawabe H, Ogata T, Hirao K, et al. Cellular insulin resistance in Epstein&#x2013;Barr virus-transformed lymphoblasts from young insulin-resistant Japanese men. Metabolism. 2005;54(3):370&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">15736115</ArticleId></ArticleIdList></Reference><Reference><Citation>De Figueiredo ASP, Salmon AB, Bruno F, Jimenez F, Martinez HG, Halade GV, et al. Nox2 mediates skeletal muscle insulin resistance induced by a high fat diet. J Biol Chem. 2015;290(21):13427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4505590</ArticleId><ArticleId IdType="pubmed">25825489</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello-Morales R, Andreu S, Ripa I, L&#xf3;pez-Guerrero JA. HSV-1 and endogenous retroviruses as risk factors in demyelination. Int J Mol Sci. 2021;22(11):5738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8199333</ArticleId><ArticleId IdType="pubmed">34072259</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutkowski N, Conrad B, Thorley-Lawson DA, Huber BT. Epstein&#x2013;Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity. 2001;15(4):579&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">11672540</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamdy A, Leonardi A. Superantigens and SARS-CoV-2. Pathogens. 2022;11(4):390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9026686</ArticleId><ArticleId IdType="pubmed">35456065</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas I, Khan GA. Coagulation disorders in COVID-19: role of toll-like receptors. J Inflamm Res. 2020;13:823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7605922</ArticleId><ArticleId IdType="pubmed">33149655</ArticleId></ArticleIdList></Reference><Reference><Citation>Anabel AS, Eduardo PC, Pedro Antonio HC, Carlos SM, Juana NM, Honorio TA, et al. Human platelets express toll-like receptor 3 and respond to poly I:C. Hum Immunol. 2014;75(12):1244&#x2013;1251.</Citation><ArticleIdList><ArticleId IdType="pubmed">25315747</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucheryavykh LY, D&#xe1;vila-Rodr&#xed;guez J, Rivera-Aponte DE, Zueva LV, Washington AV, Sanabria P, et al. Platelets are responsible for the accumulation of &#x3b2;-amyloid in blood clots inside and around blood vessels in mouse brain after thrombosis. Brain Res Bull. 2017;128:98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5205543</ArticleId><ArticleId IdType="pubmed">27908798</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn HJ, Zamolodchikov D, Cortes-Canteli M, Norris EH, Glickman JF, Strickland S. Alzheimer&#x2019;s disease peptide &#x3b2;-amyloid interacts with fibrinogen and induces its oligomerization. Proc Natl Acad Sci USA. 2010;107(50):21812&#x2013;21817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003082</ArticleId><ArticleId IdType="pubmed">21098282</ArticleId></ArticleIdList></Reference><Reference><Citation>Eimer WA, Vijaya Kumar DK, Navalpur Shanmugam NK, Rodriguez AS, Mitchell T, Washicosky KJ, et al. Alzheimer&#x2019;s disease-associated &#x3b2;-amyloid is rapidly seeded by herpesviridae to protect against brain infection. Neuron. 2018;99(1):56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6075814</ArticleId><ArticleId IdType="pubmed">30001512</ArticleId></ArticleIdList></Reference><Reference><Citation>Bortolotti D, Gentili V, Rotola A, Caselli E, Rizzo R. HHV-6A infection induces amyloid-beta expression and activation of microglial cells. Alzheimers Res Ther. 2019;11(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6909659</ArticleId><ArticleId IdType="pubmed">31831060</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuret T, Lakota K, Mali P, &#x10c;u&#x10d;nik S, Praprotnik S, Tom&#x161;i&#x10d; M, et al. Naturally occurring antibodies against serum amyloid A reduce IL-6 release from peripheral blood mononuclear cells. PLoS ONE. 2018;13(4):e0195346. doi: 10.1371/journal.pone.0195346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0195346</ArticleId><ArticleId IdType="pmc">PMC5884545</ArticleId><ArticleId IdType="pubmed">29617422</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, Thomson GJA, Nunes JM, Engelbrecht AM, Nell TA, de Villiers WJS, et al. Serum amyloid A binds to fibrin(ogen), promoting fibrin amyloid formation. Sci Rep. 2019;9(1):1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6395759</ArticleId><ArticleId IdType="pubmed">30816210</ArticleId></ArticleIdList></Reference><Reference><Citation>Violi F, Oliva A, Cangemi R, Ceccarelli G, Pignatelli P, Carnevale R, et al. Nox2 activation in Covid-19. Redox Biol. 2020;36:101655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7381406</ArticleId><ArticleId IdType="pubmed">32738789</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C-S, Kim J-J, Lee SJ, Hwang JH, Lee C-H, Lee M-S, et al. TLR3-triggered reactive oxygen species contribute to inflammatory responses by activating signal transducer and activator of transcription-1. J Immunol. 2013;190(12):6368&#x2013;6377.</Citation><ArticleIdList><ArticleId IdType="pubmed">23670194</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson G. Linking the biological underpinnings of depression: role of mitochondria interactions with melatonin, inflammation, sirtuins, tryptophan catabolites, DNA repair and oxidative and nitrosative stress, with consequences for classification and cognition. Prog Neuro-Psychopharmacol Biol Psychiatry. 2018;80:255&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">28433458</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuomi T, Nagorny CLF, Singh P, Bennet H, Yu Q, Alenkvist I, et al. Increased melatonin signaling is a risk factor for type 2 diabetes. Cell Metab. 2016;23(6):1067&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">27185156</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehraj V, Routy J-P. Tryptophan catabolism in chronic viral infections: handling uninvited guests. Int J Tryptophan Res. 2015;8:41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4527356</ArticleId><ArticleId IdType="pubmed">26309411</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams O, Besken K, Oberd&#xf6;rfer C, MacKenzie CR, R&#xfc;&#xdf;ing D, D&#xe4;ubener W. Inhibition of human herpes simplex virus type 2 by interferon gamma and tumor necrosis factor alpha is mediated by indoleamine 2,3-dioxygenase. Microbes Infect. 2004;6(9):806&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pubmed">15374002</ArticleId></ArticleIdList></Reference><Reference><Citation>Burassakarn A, Srisathaporn S, Pientong C, Wongjampa W, Vatanasapt P, Patarapadungkit N, et al. Exosomes-carrying Epstein&#x2013;Barr virus-encoded small RNA-1 induces indoleamine 2, 3-dioxygenase expression in tumor-infiltrating macrophages of oral squamous-cell carcinomas and suppresses T-cell activity by activating RIG-I/IL-6/TNF-&#x3b1; pathway. Oral Oncol. 2021;117:105279.</Citation><ArticleIdList><ArticleId IdType="pubmed">33819809</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H, Gong J, Liu Y. Indoleamine 2, 3-dioxygenase regulation of immune response (review) Mol Med Rep. 2018;17(4):4867&#x2013;4873. doi: 10.3892/mmr.2018.8537/abstract.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2018.8537/abstract</ArticleId><ArticleId IdType="pubmed">29393500</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010;185(6):3190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2952546</ArticleId><ArticleId IdType="pubmed">20720200</ArticleId></ArticleIdList></Reference><Reference><Citation>Krupa A, Kowalska I. The kynurenine pathway&#x2014;new linkage between innate and adaptive immunity in autoimmune endocrinopathies. Int J Mol Sci. 2021;22(18):9879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8469440</ArticleId><ArticleId IdType="pubmed">34576041</ArticleId></ArticleIdList></Reference><Reference><Citation>Song H, Park H, Kim J, Park G, Kim YS, Kim SM, et al. IDO metabolite produced by EBV-transformed B cells inhibits surface expression of NKG2D in NK cells via the c-Jun N-terminal kinase (JNK) pathway. Immunol Lett. 2011;136(2):187&#x2013;193. doi: 10.1016/j.imlet.2011.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2011.01.009</ArticleId><ArticleId IdType="pubmed">21277902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin W, Shen P, Song Y, Huang Y, Tu S. Reactive oxygen species in autoimmune cells: function, differentiation, and metabolism. Front Immunol. 2021;12:488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7946999</ArticleId><ArticleId IdType="pubmed">33717180</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels I, Maywald M, Rink L. Zinc as a gatekeeper of immune function. Nutrients. 2017;9(12):1286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5748737</ArticleId><ArticleId IdType="pubmed">29186856</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai H, Wang L, Li L, Huang Z, Ye L. Metallothionein 1: a new spotlight on inflammatory diseases. Front Immunol. 2021;12:739918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8602684</ArticleId><ArticleId IdType="pubmed">34804020</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarczyk M, Favre M. Role of Zn2+ ions in host&#x2013;virus interactions. J Virol. 2008;82(23):11486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2583646</ArticleId><ArticleId IdType="pubmed">18787005</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignesh KS, Deepe GS. Metallothioneins: emerging modulators in immunity and infection. Int J Mol Sci. 2017;18(10):2197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5666878</ArticleId><ArticleId IdType="pubmed">29065550</ArticleId></ArticleIdList></Reference><Reference><Citation>Ollig J, Kloubert V, Taylor KM, Rink L. B cell activation and proliferation increase intracellular zinc levels. J Nutr Biochem. 2019;64:72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6372723</ArticleId><ArticleId IdType="pubmed">30448545</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo M, Itoh N, Kawasaki A, Tanaka J, Nakanishi T, Tanaka K. Zinc-induced activation of the human cytomegalovirus major immediate-early promoter is mediated by metallothionein and nuclear factor-&#x3ba;B. Toxicol Appl Pharmacol. 2001;173(3):146&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">11437636</ArticleId></ArticleIdList></Reference><Reference><Citation>Aras S, Singh G, Johnston K, Foster T, Aiyar A. Zinc coordination is required for and regulates transcription activation by Epstein&#x2013;Barr nuclear antigen 1. PLoS Pathog. 2009;5(6):e1000469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2690687</ArticleId><ArticleId IdType="pubmed">19521517</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Li L, Li L, Ding L, Liu X, Chen X, et al. Metallothionein-1 suppresses rheumatoid arthritis pathogenesis by shifting the Th17/Treg balance. Eur J Immunol. 2018;48(9):1550&#x2013;1562. doi: 10.1002/eji.201747151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201747151</ArticleId><ArticleId IdType="pubmed">30055006</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin X, Knecht DA, Lynes MA. Metallothionein mediates leukocyte chemotaxis. BMC Immunol. 2005;6:21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1262721</ArticleId><ArticleId IdType="pubmed">16164753</ArticleId></ArticleIdList></Reference><Reference><Citation>Avan A, Cz&#x142;onkowska A, Gaskin S, Granzotto A, Sensi SL, Hoogenraad TU. The role of zinc in the treatment of Wilson&#x2019;s disease. Int J Mol Sci. 2022;23(16):9316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9409413</ArticleId><ArticleId IdType="pubmed">36012580</ArticleId></ArticleIdList></Reference><Reference><Citation>Waeytens A, De Vos M, Laukens D. Evidence for a potential role of metallothioneins in inflammatory bowel diseases. Mediat Inflamm. 2009 doi: 10.1155/2009/729172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2009/729172</ArticleId><ArticleId IdType="pmc">PMC2734936</ArticleId><ArticleId IdType="pubmed">19727408</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatineni V, An JY, Leffew MR, Mahesh SA. Anemia from A to zinc: hypocupremia in the setting of gastric bypass and zinc excess. Clin Case Rep. 2020;8(4):745&#x2013;750. doi: 10.1002/ccr3.2741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccr3.2741</ArticleId><ArticleId IdType="pmc">PMC7141722</ArticleId><ArticleId IdType="pubmed">32274050</ArticleId></ArticleIdList></Reference><Reference><Citation>Prohaska JR. Impact of copper limitation on expression and function of multicopper oxidases (ferroxidases) Adv Nutr. 2011;2(2):89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065751</ArticleId><ArticleId IdType="pubmed">22332037</ArticleId></ArticleIdList></Reference><Reference><Citation>Babak MV, Ahn D. Modulation of intracellular copper levels as the mechanism of action of anticancer copper complexes: clinical relevance. Biomedicines. 2021;9(8):852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389626</ArticleId><ArticleId IdType="pubmed">34440056</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Bella LM, Alampi R, Biundo F, Toscano G, Felice MR. Copper chelation and interleukin-6 proinflammatory cytokine effects on expression of different proteins involved in iron metabolism in HepG2 cell line. BMC Biochem. 2017;18(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5259844</ArticleId><ArticleId IdType="pubmed">28118841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakhautdin B, Febbraio M, Goksoy E, De La Motte CA, Gulen MF, Childers EP, et al. Protective role of macrophage-derived ceruloplasmin in inflammatory bowel disease. Gut. 2013;62(2):209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3595056</ArticleId><ArticleId IdType="pubmed">22345661</ArticleId></ArticleIdList></Reference><Reference><Citation>Montes S, Rivera-Mancia S, Diaz-Ruiz A, Tristan-Lopez L, Rios C. Copper and copper proteins in Parkinson&#x2019;s disease. Oxid Med Cell Longev. 2014 doi: 10.1155/2014/147251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/147251</ArticleId><ArticleId IdType="pmc">PMC3941957</ArticleId><ArticleId IdType="pubmed">24672633</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel BN, Dunn RJ, Jeong SY, Zhu Q, Julien JP, David S. Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J Neurosci. 2002;22(15):6578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758125</ArticleId><ArticleId IdType="pubmed">12151537</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagheri S, Saboury AA, Haertl&#xe9; T, Rongioletti M, Saso L. Probable reasons for neuron copper deficiency in the brain of patients with Alzheimer&#x2019;s disease: the complex role of amyloid. Inorganics. 2022;10(1):6.</Citation></Reference><Reference><Citation>Wang Y, Chen Y, Zhang X, Lu Y, Chen H. New insights in intestinal oxidative stress damage and the health intervention effects of nutrients: a review. J Funct Foods. 2020;75:104248.</Citation></Reference><Reference><Citation>Kehoe CA, Faughnan MS, Gilmore WS, Coulter JS, Howard AN, Strain JJ. Plasma diamine oxidase activity is greater in copper-adequate than copper-marginal or copper-deficient rats. J Nutr. 2000;130(1):30&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">10613762</ArticleId></ArticleIdList></Reference><Reference><Citation>Legleiter LR, Spears JW. Plasma diamine oxidase: a biomarker of copper deficiency in the bovine. J Anim Sci. 2007;85(9):2198&#x2013;2204.</Citation><ArticleIdList><ArticleId IdType="pubmed">17526663</ArticleId></ArticleIdList></Reference><Reference><Citation>Comas-Bast&#xe9; O, S&#xe1;nchez-P&#xe9;rez S, Veciana-Nogu&#xe9;s MT, Latorre-Moratalla M, Vidal-Carou MDC. Histamine intolerance: the current state of the art. Biomolecules. 2020;10(8):1&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7463562</ArticleId><ArticleId IdType="pubmed">32824107</ArticleId></ArticleIdList></Reference><Reference><Citation>Bortolato M, Chen K, Shih JC. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev. 2008;60(13&#x2013;14):1527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2630537</ArticleId><ArticleId IdType="pubmed">18652859</ArticleId></ArticleIdList></Reference><Reference><Citation>Yabut JM, Crane JD, Green AE, Keating DJ, Khan WI, Steinberg GR. Emerging roles for serotonin in regulating metabolism: new implications for an ancient molecule. Endocr Rev. 2019;40(4):1092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6624793</ArticleId><ArticleId IdType="pubmed">30901029</ArticleId></ArticleIdList></Reference><Reference><Citation>Bala S, Lunney JK, Failla ML. Effects of copper deficiency on T-cell mitogenic responsiveness and phenotypic profile of blood mononuclear cells from swine. Am J Vet Res. 1992;53(7):1231&#x2013;1235.</Citation><ArticleIdList><ArticleId IdType="pubmed">1386716</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Zhu J, Xu L, Wang B, Lin W, Luo Y. Copper regulation of immune response and potential implications for treating orthopedic disorders. Front Mol Biosci. 2022;9:1311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9762617</ArticleId><ArticleId IdType="pubmed">36545506</ArticleId></ArticleIdList></Reference><Reference><Citation>Cz&#x142;onkowska A, Milewski B. Immunological observations on patients with Wilson&#x2019;s disease. J Neurol Sci. 1976;29(2&#x2013;4):411&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">978218</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganaraja B, Pavithran P, Ghosh S. Effect of estrogen on plasma ceruloplasmin level in rats exposed to acute stress. Indian J Med Sci. 2004;58(4):150&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">15122050</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T, Johnston S, Clarke L, Smith P, Staines D, Marshall-Gradisnik S. Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels. Clin Exp Immunol. 2017;187(2):284. doi: 10.1111/cei.12882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.12882</ArticleId><ArticleId IdType="pmc">PMC5217865</ArticleId><ArticleId IdType="pubmed">27727448</ArticleId></ArticleIdList></Reference><Reference><Citation>Mihaylova I, DeRuyter M, Rummens JL, Bosmans E, Maes M. Decreased expression of CD69 in chronic fatigue syndrome in relation to inflammatory markers: evidence for a severe disorder in the early activation of T lymphocytes and natural killer cells. Neuro Endocrinol Lett. 2007;28(4):477&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">17693977</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenu EW, van Driel ML, Staines DR, Ashton KJ, Ramos SB, Keane J, et al. Immunological abnormalities as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med. 2011;9(1):81. doi: 10.1186/1479-5876-9-81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-9-81</ArticleId><ArticleId IdType="pmc">PMC3120691</ArticleId><ArticleId IdType="pubmed">21619669</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eeden C, Osman MS, Willem J, Tervaert C, Cohen Tervaert JW. Fatigue in ANCA-associated vasculitis (AAV) and systemic sclerosis (SSc): similarities with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Crit Rev Lit. 2022 doi: 10.1080/1744666X.2022.2116002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2022.2116002</ArticleId><ArticleId IdType="pubmed">36045606</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J-S, Lacerda EM, Nacul L, Kingdon CC, Norris J, O&#x2019;Boyle S, et al. Salivary DNA loads for human herpesviruses 6 and 7 are correlated with disease phenotype in myalgic encephalomyelitis/chronic fatigue syndrome. Front Med. 2021 doi: 10.3389/fmed.2021.656692.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.656692</ArticleId><ArticleId IdType="pmc">PMC8378328</ArticleId><ArticleId IdType="pubmed">34422848</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xe9;mont M, Metzger K, Rady HF, Hulstaert J, De MKD. Detection of herpesviruses and parvovirus B19 in gastric and intestinal mucosa of chronic fatigue syndrome patients. In Vivo. 2009;23(2):209&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">19414405</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasa S, Chapenko S, Krumina A, Zazerska Z, Murovska M. Occurrence, phase and status of human parvovirus B19 infection in patients with myalgic encephalomyelitis/chronic fatigue syndrome. J Clin Virol. 2016;82:S141.</Citation></Reference><Reference><Citation>Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lemer AM, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. J Chronic Fatigue Syndr. 2003;11(1):7&#x2013;115. doi: 10.1300/J092v11n01_02.</Citation><ArticleIdList><ArticleId IdType="doi">10.1300/J092v11n01_02</ArticleId></ArticleIdList></Reference><Reference><Citation>Strahler J, Fischer S, Nater UM, Ehlert U, Gaab J. Norepinephrine and epinephrine responses to physiological and pharmacological stimulation in chronic fatigue syndrome. Biol Psychol. 2013;94(1):160&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">23770415</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavyani B, Lidbury BA, Schloeffel R, Fisher PR, Missailidis D, Annesley SJ, et al. Could the kynurenine pathway be the key missing piece of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) complex puzzle? Cell Mol Life Sci. 2022;79(8):1&#x2013;19. doi: 10.1007/s00018-022-04380-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-022-04380-5</ArticleId><ArticleId IdType="pmc">PMC9276562</ArticleId><ArticleId IdType="pubmed">35821534</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680424</ArticleId><ArticleId IdType="pubmed">19150053</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavares RG, Tasca CI, Santos CES, Alves LB, Porci&#xfa;ncula LO, Emanuelli T, et al. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int. 2002;40(7):621&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">11900857</ArticleId></ArticleIdList></Reference><Reference><Citation>Renz-Polster H, Tremblay ME, Bienzle D, Fischer JE. The pathobiology of myalgic encephalomyelitis/chronic fatigue syndrome: the case for neuroglial failure. Front Cell Neurosci. 2022;16:220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9124899</ArticleId><ArticleId IdType="pubmed">35614970</ArticleId></ArticleIdList></Reference><Reference><Citation>Glassford JAG. The neuroinflammatory etiopathology of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Front Physiol. 2017;8(2):88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5314655</ArticleId><ArticleId IdType="pubmed">28261110</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurup RK, Kurup PA. Isoprenoid pathway dysfunction in chronic fatigue syndrome. Acta Neuropsychiatr. 2003;15(5):266&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">26983655</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M, Mihaylova I, De Ruyter M. Lower serum zinc in chronic fatigue syndrome (CFS): relationships to immune dysfunctions and relevance for the oxidative stress status in CFS. J Affect Disord. 2006;90(2&#x2013;3):141&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">16338007</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasso EM, Muraki K, Eaton-Fitch N, Smith P, Lesslar OL, Deed G, et al. Transient receptor potential melastatin 3 dysfunction in post COVID-19 condition and myalgic encephalomyelitis/chronic fatigue syndrome patients. Mol Med. 2022;28(1):1&#x2013;14. doi: 10.1186/s10020-022-00528-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-022-00528-y</ArticleId><ArticleId IdType="pmc">PMC9388968</ArticleId><ArticleId IdType="pubmed">35986236</ArticleId></ArticleIdList></Reference><Reference><Citation>Vig&#xf3;n L, Gal&#xe1;n M, Mateos E, Garc&#xed;a-P&#xe9;rez J, Torres M, Rodr&#xed;guez-Mora S, et al. Impaired cytotoxic immune response and EBV reactivation in patients with long COVID19. Top Antivir Med. 2022;30:119&#x2013;120.</Citation></Reference><Reference><Citation>Esp&#xed;n E, Yang C, Shannon CP, Assadian S, He D, Tebbutt SJ. Cellular and molecular biomarkers of long COVID: a scoping review. EBioMedicine. 2023;91:104552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10082390</ArticleId><ArticleId IdType="pubmed">37037165</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiech M, Chroscicki P, Swatler J, Stepnik D, De Biasi S, Hampel M, et al. Remodeling of T cell dynamics during long COVID is dependent on severity of SARS-CoV-2 infection. Front Immunol. 2022;13:886431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9226563</ArticleId><ArticleId IdType="pubmed">35757700</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukocheva OA, Maksoud R, Beeraka NM, Madhunapantula SRV, Sinelnikov M, Nikolenko VN, et al. Analysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome. J Adv Res. 2022;40:179&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8619886</ArticleId><ArticleId IdType="pubmed">36100326</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;23(2):194&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollbracht C, Kraft K. Oxidative stress and hyper-inflammation as major drivers of severe COVID-19 and long COVID: implications for the benefit of high-dose intravenous vitamin C. Front Pharmacol. 2022;13:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9100929</ArticleId><ArticleId IdType="pubmed">35571085</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Hakeim HK, Al-Rubaye HT, Al-Hadrawi DS, Almulla AF, Maes M. Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: a proof of concept and mechanism study. Mol Psychiatry. 2022;28(2):564&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9589528</ArticleId><ArticleId IdType="pubmed">36280755</ArticleId></ArticleIdList></Reference><Reference><Citation>Stufano A, Isgr&#xf2; C, Palese LL, Caretta P, De Maria L, Lovreglio P, et al. Oxidative damage and post-COVID syndrome: a cross-sectional study in a cohort of italian workers. Int J Mol Sci. 2023;24(8):7445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10139201</ArticleId><ArticleId IdType="pubmed">37108606</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda Y, Tokumasu K, Otsuka Y, Sunada N, Honda H, Sakurada Y, et al. Symptomatic characteristics of hypozincemia detected in long COVID patients. J Clin Med. 2023;12(5):2062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10004579</ArticleId><ArticleId IdType="pubmed">36902849</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapkota HR, Nune A. Long COVID from rheumatology perspective&#x2014;a narrative review. Clin Rheumatol. 2022;41(2):337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8629735</ArticleId><ArticleId IdType="pubmed">34845562</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris D, Patel K, Rahimi O, Sanyurah O, Iardino A, Khan N. ANCA vasculitis: a manifestation of post-Covid-19 syndrome. Respir Med Case Rep. 2021;34:101549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8580553</ArticleId><ArticleId IdType="pubmed">34786334</ArticleId></ArticleIdList></Reference><Reference><Citation>Milic J, Barbieri S, Gozzi L, Brigo A, Begh&#xe9; B, Verduri A, et al. Metabolic-associated fatty liver disease is highly prevalent in the postacute COVID syndrome. Open Forum Infect Dis. 2022 doi: 10.1093/ofid/ofac003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac003</ArticleId><ArticleId IdType="pmc">PMC8826155</ArticleId><ArticleId IdType="pubmed">35146047</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherer PE, Kirwan JP, Rosen CJ. Post-acute sequelae of COVID-19: a metabolic perspective. Elife. 2022;11:78200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942467</ArticleId><ArticleId IdType="pubmed">35318939</ArticleId></ArticleIdList></Reference><Reference><Citation>Bizjak DA, Stangl M, B&#xf6;rner N, B&#xf6;sch F, Durner J, Drunin G, et al. Kynurenine serves as useful biomarker in acute, long- and post-COVID-19 diagnostics. Front Immunol. 2022 doi: 10.3389/fimmu.2022.1004545/full.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1004545/full</ArticleId><ArticleId IdType="pmc">PMC9537769</ArticleId><ArticleId IdType="pubmed">36211365</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LC, Nersisyan S, Wu CJ, Chang CM, Tonevitsky A, Guo CL, et al. On the peptide binding affinity changes in population-specific HLA repertoires to the SARS-CoV-2 variants Delta and Omicron. J Autoimmun. 2022;133:102952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9650568</ArticleId><ArticleId IdType="pubmed">36427410</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer C, Stein J, Southwood S, Ketelaar H, Sette A, Bottomly K. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med. 1995;181(4):1569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2191965</ArticleId><ArticleId IdType="pubmed">7699337</ArticleId></ArticleIdList></Reference><Reference><Citation>Nersisyan S, Zhiyanov A, Zakharova M, Ishina I, Kurbatskaia I, Mamedov A, et al. Alterations in SARS-CoV-2 Omicron and Delta peptides presentation by HLA molecules. PeerJ. 2022;10:e13354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9055995</ArticleId><ArticleId IdType="pubmed">35502206</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Duong D. The evolving picture of long COVID. Can Med Assoc J. 2022;194(24):E850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9261954</ArticleId><ArticleId IdType="pubmed">35724998</ArticleId></ArticleIdList></Reference><Reference><Citation>Elenkov IJ. Glucocorticoids and the Th1/Th2 balance. Ann N Y Acad Sci. 2004;1024:138&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">15265778</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang EV, WebsterMarketon JI, Chen M, Lo KW, Kim SJ, Glaser R. Glucocorticoids activate Epstein Barr virus lytic replication through the upregulation of immediate early BZLF1 gene expression. Brain Behav Immun. 2010;24(7):1089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2939213</ArticleId><ArticleId IdType="pubmed">20466055</ArticleId></ArticleIdList></Reference><Reference><Citation>Celada P, Puig MV, Amarg&#xf3;s-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci. 2004;29(4):252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC446220</ArticleId><ArticleId IdType="pubmed">15309042</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan M, Ding L, Wang D, Han J, Gao P. Serotonin: a potent immune cell modulator in autoimmune diseases. Front Immunol. 2020;11:186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7026253</ArticleId><ArticleId IdType="pubmed">32117308</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV. Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Front Pharmacol. 2021;12:652688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8094534</ArticleId><ArticleId IdType="pubmed">33959018</ArticleId></ArticleIdList></Reference><Reference><Citation>Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552828</ArticleId><ArticleId IdType="pubmed">28776086</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolova N, Iannantuoni F, Gruevska A, Muntane J, Rocha M, Victor VM. Mechanisms of action of metformin in type 2 diabetes: effects on mitochondria and leukocyte-endothelium interactions. Redox Biol. 2020;34:101517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7296337</ArticleId><ArticleId IdType="pubmed">32535544</ArticleId></ArticleIdList></Reference><Reference><Citation>Comhaire F, Deslypere JP. News and views in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): the role of co-morbidity and novel treatments. Med Hypotheses. 2020;134:109444.</Citation><ArticleIdList><ArticleId IdType="pubmed">31669858</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AE, Dibnah B, Fisher E, Newton JL, Walker M. Pharmacological activation of AMPK and glucose uptake in cultured human skeletal muscle cells from patients with ME/CFS. Biosci Rep. 2018;38(3):BSR20180242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5938427</ArticleId><ArticleId IdType="pubmed">29654166</ArticleId></ArticleIdList></Reference><Reference><Citation>Wissler Gerdes EO, Vanichkachorn G, Verdoorn BP, Hanson GJ, Joshi AY, Murad MH, et al. Role of senescence in the chronic health consequences of COVID-19. Transl Res. 2022;241:96&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8532377</ArticleId><ArticleId IdType="pubmed">34695606</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YQ, Zhang ZX, Xu YJ, Ni W, Chen SX, Yang Z, et al. N-Acetyl-l-cysteine and pyrrolidine dithiocarbamate inhibited nuclear factor-kappaB activation in alveolar macrophages by different mechanisms. Acta Pharmacol Sin. 2006;27(3):339&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pubmed">16490171</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X, Lampraki EM, Al-Khalidi S, Qureshi MA, Desai R, Wilson JB. N-Acetylcysteine (NAC) ameliorates Epstein&#x2013;Barr virus latent membrane protein 1 induced chronic inflammation. PLoS ONE. 2017;12(12):e0189167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5724866</ArticleId><ArticleId IdType="pubmed">29228057</ArticleId></ArticleIdList></Reference><Reference><Citation>McQueen G, Lally J, Collier T, Zelaya F, Lythgoe DJ, Barker GJ, et al. Effects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia. Psychopharmacology. 2018;235(10):3045.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6182588</ArticleId><ArticleId IdType="pubmed">30141055</ArticleId></ArticleIdList></Reference><Reference><Citation>Olechnowicz J, Tinkov A, Skalny A, Suliburska J. Zinc status is associated with inflammation, oxidative stress, lipid, and glucose metabolism. J Physiol Sci. 2018;68(1):19&#x2013;31. doi: 10.1007/s12576-017-0571-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12576-017-0571-7</ArticleId><ArticleId IdType="pmc">PMC5754376</ArticleId><ArticleId IdType="pubmed">28965330</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Burton EM, Bhaduri-McIntosh S. Chloroquine triggers Epstein&#x2013;Barr virus replication through phosphorylation of KAP1/TRIM28 in Burkitt lymphoma cells. PLoS Pathog. 2017;13(3):e1006249. doi: 10.1371/journal.ppat.1006249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006249</ArticleId><ArticleId IdType="pmc">PMC5348047</ArticleId><ArticleId IdType="pubmed">28249048</ArticleId></ArticleIdList></Reference><Reference><Citation>Doboszewska U, Wla&#x17a; P, Nowak G, M&#x142;yniec K. Targeting zinc metalloenzymes in coronavirus disease 2019. Br J Pharmacol. 2020;177(21):4887&#x2013;4898. doi: 10.1111/bph.15199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15199</ArticleId><ArticleId IdType="pmc">PMC7405164</ArticleId><ArticleId IdType="pubmed">32671829</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim ML, Hardy MY, Edgington-Mitchell LE, Ramarathinam SH, Chung SZ, Russell AK, et al. Hydroxychloroquine inhibits the mitochondrial antioxidant system in activated T cells. iScience. 2021;24(12):103509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8661543</ArticleId><ArticleId IdType="pubmed">34934928</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasmi A, Peana M, Noor S, Lysiuk R, Menzel A, Gasmi Benahmed A, et al. Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story. Appl Microbiol Biotechnol. 2021;105(4):1333&#x2013;1343. doi: 10.1007/s00253-021-11094-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-021-11094-4</ArticleId><ArticleId IdType="pmc">PMC7847229</ArticleId><ArticleId IdType="pubmed">33515285</ArticleId></ArticleIdList></Reference><Reference><Citation>De Wolde SD, Hulskes RH, Weenink RP, Hollmann MW, Van Hulst RA. The effects of hyperbaric oxygenation on oxidative stress, inflammation and angiogenesis. Biomolecules. 2021;11(8):11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8394403</ArticleId><ArticleId IdType="pubmed">34439876</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilberman-Itskovich S, Catalogna M, Sasson E, Elman-Shina K, Hadanny A, Lang E, et al. Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial. Sci Rep. 2022;12(1):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9276805</ArticleId><ArticleId IdType="pubmed">35821512</ArticleId></ArticleIdList></Reference><Reference><Citation>Tok F, Akarsu S. The efficacy of hyperbaric oxygen therapy in the management of chronic fatigue syndrome. Undersea Hyperb Med J. 2013;40(2):197&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">23682549</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu PJ, Balfe P, McKeating JA, Schilling M. Oxygen sensing and viral replication: implications for tropism and pathogenesis. Viruses. 2020;12(11):1213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7693908</ArticleId><ArticleId IdType="pubmed">33113858</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang JH, Wang N, Li A, Liao WT, Pan ZG, Mai SJ, et al. Hypoxia can contribute to the induction of the Epstein&#x2013;Barr virus (EBV) lytic cycle. J Clin Virol. 2006;37(2):98&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">16931136</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghi MK, Liu TC, Rabkin S, Martuza RL. Hypoxia enhances the replication of oncolytic herpes simplex virus. Mol Ther. 2009;17(1):51&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823294</ArticleId><ArticleId IdType="pubmed">18957963</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Yu C, Jing H, Wu X, Novakovic VA, Xie R, et al. Long COVID: the nature of thrombotic sequelae determines the necessity of early anticoagulation. Front Cell Infect Microbiol. 2022 doi: 10.3389/fcimb.2022.861703.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.861703</ArticleId><ArticleId IdType="pmc">PMC9016198</ArticleId><ArticleId IdType="pubmed">35449732</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>